Synthetic intron compositions to target u2AF1 mutant cancers

Synthetic intron constructs with heterologous promoters and intron domains selectively target and eliminate U2AF1 mutant cancer cells, addressing the lack of effective therapies for these conditions by preferential splicing and potential gene expression.

WO2026236214A1PCT designated stage Publication Date: 2026-11-12MEMORIAL SLOAN KETTERING CANCER CENT +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026692
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapeutic strategies fail to selectively target and eliminate U2AF1 mutant cancer cells, which are prevalent in conditions like myelodysplastic syndromes and non-small cell lung adenocarcinomas, leading to adverse outcomes.

Method used

Development of synthetic intron constructs comprising a heterologous promoter and an intron domain derived from naturally occurring sequences of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B, which are differentially spliced in U2AF1 mutant cells, potentially incorporating fluorescent proteins or suicide genes to selectively eliminate these cells.

Benefits of technology

The synthetic intron constructs effectively target and eliminate U2AF1 mutant cancer cells by preferential splicing, offering a precise therapeutic approach to treat conditions such as myelodysplastic syndromes, myeloid cancer, and lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026692_12112026_PF_FP_ABST
    Figure US2026026692_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are synthetic introns that are selectively and efficiently spliced in U2AF1 -mutant cancer cells, but unspliced in wild-type cells, to yield mutation-dependent protein production. The synthetic intron constructs of the present technology are useful in methods for treating a U2AF1 -mutant cancer in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Atty. Dkt. No.: 115872-3526SYNTHETIC INTRON COMPOSITIONS TO TARGET U2AF1 MUTANT CANCERS CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Appl. No.63 / 800,921, filed May 6, 2025, the contents of which are incorporated herein by reference in its entirety for any and all purposes.TECHNICAL FIELD

[0002] Disclosed herein are MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic introns that are selectively and efficiently spliced in U2AF1 -mutant cancer cells, but unspliced in wild-type cells. The MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs of the present technology are useful in methods for treating a U2AF1 -mutant cancer in a subject in need thereof.BACKGROUND

[0003] The following description of the background of the present technology is provided simply as an aid in understanding the present technology and is not admitted to describe or constitute prior art to the present technology.

[0004] Mutations affecting the core RNA splicing factors SF3B1, U2AF1, and SRSF2 are the most common class of mutations across cancers (e.g., myelodysplastic syndromes (MDS) and related myeloid neoplasms). Auxiliary factor U2AF1 heterodimerizes with U2AF2 and recognizes the 3’ AG dinucleotide at the splice acceptor site. Mutations in U2AF1 at the S34 residue in its first zinc-finger domain are prevalent in MDS (5%— 15% of patients), and AML (5%— 17%), and non-small cell lung adenocarcinomas (3%). The S34F / Y mutation promotes alternative 3’ splice site usage and impacts a restricted set of alternative splicing events. Patients with U2AF1 mutations are associated with adverse outcomes. However, therapeutic strategies to selectively target U2AF1 mutant cancer cells has not been identified.

[0005] Accordingly, there is an urgent need for precision therapeutic methods that selectively target and eliminate cells carrying cancer-causing mutations affecting the RNA splicing factor U2AF 1.-1- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526SUMMARY OF THE PRESENT TECHNOLOGY

[0006] In one aspect, the present disclosure provides a synthetic intron construct comprising (a) a heterologous promoter and (b) an intron domain derived from a naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B, wherein the heterologous promoter is located upstream of the intron domain. The intron domain derived from the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B comprises (i) a 5' splice site, (ii) a canonical 3' splice site, and (iii) at least one cryptic 3' splice site. Additionally or alternatively, in some embodiments of the synthetic intron construct described herein, the intron domain comprises a sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to a sequence derived from the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B. In any of the preceding embodiments of the synthetic intron construct disclosed herein, the length of the intron domain may range from about 200-600 base pairs (bps). In any and all embodiments of the synthetic intron construct disclosed herein, the intron domain further comprises a pyrimidine-rich domain comprising at least 6 consecutive nucleotides; and / or at least one branchpoint at least 15 nucleotides upstream of the canonical 3' splice site. The heterologous promoter may be a constitutive promoter or an inducible promoter.

[0007] In any of the above embodiments of the synthetic intron construct disclosed herein, the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B comprises intron 13 of MTA1, intron 6 of TRMT13, intron 2 of PRUNE 1, intron 6 of POLB, intron 4 of RNF216, or intron 4 of DNMT3B. Additionally or alternatively, in some embodiments of the synthetic intron construct described herein, the intron domain derived from the naturally occurring intron sequence of MTA1, PRUNE!, TRMT13, POLB, RNF216, or DNMT3B is flanked by an upstream first exon domain and a downstream second exon domain. In certain embodiments, the synthetic intron construct of the present technology comprises intron 13 of MTA1 flanked by exon 13 and exon 14, intron 6 of TRMT13 flanked by exon 6 and exon 7, intron 2 of PRUNE 1 flanked by exon 2 and exon 3, intron 6 of POLB flanked by exon 6 and exon 7, intron 4 of RNF216 flanked by exon 4 and exon 5, or intron 4 of DNMT3B flanked by exon 4 and exon 5. In any and all embodiments of the synthetic intron construct described herein, the synthetic intron construct comprises the sequence of any one of SEQ ID NOs: 1-90.-2- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0008] In any of the foregoing embodiments, the synthetic intron construct of the present technology is differentially spliced in a cell comprising a mutation in U2AF1. In certain embodiments, the mutation in U2AF1 is S34F or S34Y. Additionally or alternatively, in some embodiments of the synthetic intron construct described herein, the intron domain is preferentially spliced out in the cell comprising the mutation in U2AF1, whereas the intron domain is partially spliced out in a cell without the mutation in U2AF1, such that a portion of the intron domain is not excised from a mature U2AF1 transcript.

[0009] Additionally or alternatively, in some embodiments, the synthetic intron construct of the present technology further comprises a fluorescent protein. Examples of fluorescent proteins include, but are not limited to, TagBFP, Azurite, EBFP2, mKalamal, Sirius, Sapphire, T-Sapphire, ECFP, Cerulean, SCFP3A, mTurquoise, monomeric Midoriishi-Cyan, TagCFP, mTFPl, EGFP, Emerald, Superfolder GFP, Monomeric Azami Green, TagGFP2, mUKG, mWasabi, EYFP, Citrine, Venus, SYFP2, TagYFP, Monomeric Kusabira-Orange, mKOK, mK02, mOrange, mOrange2, mRaspberry, mCherry, dsRed, mStrawberry, mTangerine, tdTomato, TagRFP, TagRFP-T, mApple, mRuby, mPlum, HcRed-Tandem, mKate2, mNeptune, NirFP, TagRFP657, IFP1.4, iRFP, mKeimaRed, LSS-mKatel, LSS-mKate2, PA-GFP, PAmCherryl, PATagRFP, Kaede (green), Kaede (red), KikGRl (green), KikGRl (red), PS-CFP2, PS-CFP2, mEos2 (green), mEos2 (red), PSmOrange, or Dronpa. Additionally or alternatively, in some embodiments of the synthetic intron construct described herein, the fluorescent protein is located downstream of the intron domain.

[0010] Additionally or alternatively, in certain embodiments, the synthetic intron construct of the present technology further comprises a suicide gene. The intron domain is inserted between a first exon domain of the suicide gene and a second exon domain of the suicide gene. Additionally or alternatively, in some embodiments of the synthetic intron construct described herein, the suicide gene is herpes simplex virus thymidine kinase (HSV-TK) or inducible caspase 9 (iCasp9).

[0011] In any of the preceding embodiments, the synthetic intron construct of the present technology further comprises a cytokine. Examples of cytokines include, but are not limited to, interferon a, interferon P, interferon y, complement C5a, IL-2, TNF alpha, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL19, CCL2, CCL20,-3- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2. In certain embodiments of the synthetic intron construct disclosed herein, the cytokine and the intron domain are separated by a cleavable linker. In some embodiments, the cleavable linker is a 2A self-cleaving peptide linker selected from the group consisting of P2A, T2A, E2A, F2A and BmCPV2A.

[0012] In one aspect, the present disclosure provides a method for treating a U2AF1 mutant cancer in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the synthetic intron construct disclosed herein. In some embodiments, the U2AF1 mutant cancer is selected from among myelodysplastic syndromes (MDS), myeloid cancer (e.g., AML), lung cancer, and pancreatic cancer.

[0013] In another aspect, the present disclosure provides a method for identifying a drug candidate that inhibits mis-splicing in a U2AF1 mutant cancer cell comprising contacting the U2AF1 mutant cancer cell with an effective amount of any and all embodiments of the synthetic intron construct disclosed herein, contacting the U2AF1 mutant cancer cell with a drug candidate, and measuring proliferation of the U2AF1 mutant cancer cell. In some embodiments, the method further comprises determining that the drug candidate is effective when the proliferation of the U2AF1 mutant cancer cell is increased in the presence of the drug candidate compared to the U2AF1 mutant cancer cell without the drug candidate. Additionally or alternatively, in some embodiments, the drug candidate is a small molecule or an inhibitory RNA (e.g., siRNA, shRNA, sgRNA or antisense).

[0014] Additionally or alternatively, in certain embodiments of the methods disclosed herein, the synthetic intron construct is administered orally, intranasally, parenterally, intravenously, intramuscularly, intraperitoneally, or subcutaneously, rectally, intrathecally, intratumorally or topically. In certain embodiments of the methods disclosed herein, the synthetic intron construct is formulated with a lipid nanoparticle (LNP). The LNP may comprise a receptor that targets the U2AF1 mutant cancer cell. In some embodiments, the receptor is a Fab, a Fab’, a scFv, or a (Fab)2. Additionally or alternatively, in some-4- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526embodiments of the methods disclosed herein, the receptor targets a ligand expressed on the cell surface of the U2AF1 mutant cancer cell.BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 depicts synthetic introns to drive selective gene expression based on perturbations in RNA splicing and dissect splicing regulatory mechanisms. Synthetic introns are oligonucleotides which interrupt a protein coding sequence that are uniquely recognized in settings where the RNA splicing machinery is perturbed. These can be used to drive selective gene expression in disease settings characterized by aberrant splicing (left) or for forward genetic / chemical screens to correct aberrant splicing.

[0016] FIGs. 2A-2P. Development of initial synthetic intron for U2AF1 mutant cells. FIG. 2A: Diagram of U2AF1 protein and sites of hotspot mutations at Serine 34 or Glutamine 157, both of which are located in the RNA binding zinc finger domains of U2AF1. FIG. 2B: Heatmap illustrating isoform percent spliced-in (PSI) values for alternative 3’ splice site events differentially spliced between acute myeloid leukemia (AML) patients versus patients without the indicated mutations (wild-type (“WT”)). Each row represents isoforms and each column represents a patient transcriptome. FIG. 2C: Venn diagram of alternate 3’ splice site events in U2AF1S34mutant AML patient and K562 human AML cell line transcriptomes. 21 mis-splicing events were consistent across patient samples and cell lines and three noted in red (MTA1, PRUNE1, and TRMT13) were used for synthetic intron generation. FIG. 2D: Sequence motif analysis of alternative 3' splice sites preferentially used in U2AF1 -mutant versus wild-type contexts. Position weight matrices show the nucleotide composition at the 3' splice site for U2AF1WTand U2AF1S34Ycell lines (top), and U2AF1WT(n=138) and U2AF1S34mutant (n=9) AML patients (bottom). Consensus 3’ splice sites of cassette exons with increased or decreased inclusion in U2AF1 mutant relative to WT AML transcriptomes. Boxes highlight sequence preferences at the -3 position that differ from the normal 3’ splice site consensus. (Vertical axis) Information content in bits. FIG. 2E: Diagram of WT versus mutant splice sites used in MTA1, PRUNE1, and TRMT13. RT-PCR in K562 cells with knockin of U2AF1 S34F or S34Y mutants or WT U2AF1 at three events (mutant splice sites used in MTA1, PRUNE1, and TRMT13). FIG. 2F: Box-and-whiskers plot of PSI values of the MTA1 alternative 3’ splice site event across AML patient samples with the indicated genotypes. The number of-5- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526patients represented in each column is listed. The center line represents the median, the top and bottom of the box represent the 75th and 25th percentiles, respectively, and the top and bottom whiskers represent the maximum and minimum values excluding outliers.U2AF1S34mutant patients exhibit significantly lower PSI values compared to splicing factor wild-type patients, indicating increased alternative CAG 3' splice site usage (*** p < 0.001).FIG. 2G: Diagram of the alternative 3’ splice site in MTA1 indicating the intron proximal 3’ splice site utilized by U2AF1 WT cells and the distal 3’ splice site expressed in U2AF1 S34 mutant cells. The nucleotides used at each 3’ splice site is indicated and there is 47 nucleotides (nt) between each site. FIGs. 2H-2J: RT-PCR of MTA1 3’ splice site usage in U2AF1 WT versus U2AF1 S34 mutant (FIG. 2H) K562 AML cells, (FIG. 21) U2AF1S34transgenic cells, and (FIG. 2J) lung adenocarcinoma (H441) cells. FIG.2K: Schematic of expected splicing outcome of HSV-TK MTA1 synthetic intron in U2AF1 wild-type and U2AF1S34mutant cells. FIG. 2L: Diagram of likelihood of splice site usage predicted by SpliceAI for the (top) endogenous MTA1 exons 13-15 and (bottom) HSV-TK interrupted by intron 13 of MTA1 with the competing 3’ splice sites. FIG. 2M: RT-PCR of K562 U2AF1 WT cells transfected with the 300ng indicated U2AF1 WT and S34 cDNAs with the MTA1 synthetic intron. FIG. 2N: Viability of K562 cells WT for U2AF1 or with heterozygous U2AFlS34Yknockiin mutation transduced with test synthetic intron, intronless HSV-TK positive control cDNA, or negative control untransduced cells. Cells were treated with ganciclovir for 5 days at the indicated doses. FIG. 20: RT-PCR of K562 cells WT for U2AF1 or with heterozygous U2AF1S34Yknockin mutation express a shortened 161 nt version of the MTA-1 synthetic intron interrupting HSV-TK. FIG. 2P: Cell viability curves of cells from 2K upon ganciclovir exposure. Cells transduced with intronless HSV-TK (red) serve as positive controls while untransduced cells (grey) are negative controls.

[0017] FIGs. 3A-3L. Al-guided improvement of mutant U2AFl-selective synthetic intron. FIG. 3A: SpliceAI predicted probability of splice site usage in HSV-TK cDNA interrupted by 208nt MTA1 synthetic intron. Bottom inset indicates location of mutations generated. FIG. 3B: SpliceAI variant analysis of the impact of 624 variants in the MTA1 synthetic intron on probability of the mutant 3’ distal splice site (y-axis) versus intron proximal wild-type 3’ splice site usage (x-axis). Red star indicates value of parental intron. Colored points indicate mutants tested from FIG. 3A. FIG. 3C: RT-PCR of the parental 208nt MTA1 synthetic intron and the variants tested in FIG. 3B. FIG. 3D: Viability of -6- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526K562 cells WT for U2AF1 or with heterozygous U2AF1S34Yknock in mutation transduced with the indicated constructs. Cells were treated with ganciclovir for 5 days at the indicated doses. Mean+SD. *p<0.05, **p<0.001, ***p<0.0001. FIG. 3E: Top: Schema of 208nt MTA1 synthetic intron with intronic 129g>t mutation. Bottom: Viability of K562 cells WT for U2AF1 or with heterozygous U2AF1S34Yknock in mutation transduced with test synthetic intron, intronless HSV-TK positive control cDNA, or negative control untransduced cells. Cells were treated with ganciclovir for 5 days at the indicated doses. FIG. 3F: Representative bioluminescent images of NSG mice engrafted systemically with luciferase expressing K562 cells WT for U2AF1 or with heterozygous U2AFlS34Yknockiin mutation and expressing the 208nt MTA1 synthetic intron with intronic 129g>t mutation.FIG. 3G: Quantification of data from FIG. 2F. Cells used in all panels are K562 cells (human BCR-ABL fusion AML cells). FIG. 3H: Therapeutic impact of U2AF1 mutant selective synthetic introns in K562 AML murine model. FIG. 31: Kaplan-Meier curves of mice from FIG. 3F. FIGs. 3J-3L: Therapeutic impact of U2AF1 mutant selective synthetic introns in A549 NSCLC murine model.

[0018] FIGs. 4A-4H depict Al-guided improvement of mutant U2AFl-selective synthetic intron and molecular basis for mutant selectivity. FIG. 4A: Workflow of MTA1 synthetic intron improvement. Synthetic intron generation started with endogenous MTA1 exons 13-14 with intervening intron 13. Intron 13 (measuring 268nt in length), along with the competing 3’ splice sites, was inserted into the coding region of HSV-TK to generate an initial synthetic intron. Intron 13 was then shortened to 208nt followed by SpliceAI mutagenesis to identify the shortened synthetic intron with an intronic 129 g>t mutation. This shortened mutant intron was then iteratively evaluated by SpliceAI to identify a final synthetic intron with an additional 191 g>c mutation. FIG. 4B: SpliceAI variant analysis of the (top row) shortened synthetic intron, (middle row) shortened synthetic intron with 129 g>t mutation, and (bottom row) shortened synthetic intron with 129 g>t mutation and 191 g>c mutation. FIG. 4C: Viability of K562 cells WT for U2AF1 or with heterozygous U2AF1S34Yknockin mutation transduced with the indicated constructs. Cells were treated with ganciclovir for 5 day2 at the indicated doses. FIG. 4D: Kaplan-Meier curve of NSG mice engrafted with K562 cells WT for U2AF1 or with heterozygous U2AF1S34Yknockin mutation expressing the HSV-TK MTA1 synthetic intron with combined 129 g>t mutation and 191 g>c mutations. N=X mice / group. FIG. 4E: SpliceAI -7- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526probability score indicating likelihood single nucleotide mutations along the HSV-TK MTA1 synthetic intron impacting the mutant 3’ splice site usage. Mutations at the 174 adenosine (“A”) nucleotide and between this nucleotide and the distal 3’ splice site influence mutant 3’ splice site usage. Inset indicates nucleotides near the mutant 3’ splice site identified as impacting 3’ splice site usage. pY tract: polypyrimidine tract. FIG. 4F:RT-PCR of U2AF1 wild-type (“WT”) for U2AF1S34 mutant (“Mut”) K562 cells expressing the indicating synthetic introns. FIG. 4G: Schema of MS2-mediated mRNP purification (MMP). The HSV-TK MTA1 synthetic intron was modified to insert two MS2 hairpin loops within the intron. This allowed for purification of the intron and any bound proteins by a recombinant MBP-MS2 fusion protein, comprising MS2 coat protein (MCP) and maltose-binding protein (MBP), bound to amylose resin beads. FIG. 4H:Representative Western blotting of input or purified mRNA-protein complexes from U2AF1 isogenic K562 cells stably expressed the synthetic intron reporters. Mean+SD.

[0019] FIGs. 5A-5H depict nano-plasmid mediated delivery of synthetic introns. FIG. 5A shows bar plots of luminescence of luciferase expression in K562 cells 48 hours after delivery of vehicle (PBS), empty lipid nanoparticle (LNP), or LNPs encapsulating plasmid DNA, nanoplasmid DNA, or in vitro transcribed mRNA. 1 pg / mL of LNP delivered in each condition. Box-and-whiskers plot of luminescence relative to vehicle. FIG. 5B shows percent (%) cell viability of K562 cells 48 hours after delivery of vehicle (PBS), empty lipid nanoparticle (LNP), or LNPs encapsulating plasmid DNA, nanoplasmid DNA, or in vitro transcribed mRNA. **p<0.05 ***p<0.001. FIG. 5C shows (Top) diagram of splicing regulated mEmerald construct that was encoded in a nanoplasmid and encapsulated in LNP, and (Bottom) % of U2AF1WTK562 cells expressing mEmerald using the LNP delivery of nanoplasmid encoding the splicing regulated mEmerald construct above. FIG. 5D shows representative FACS plots of mEmerald expression overtime from (FIG. 5C) for untreated cells and cells treated with 0.5 pg / mL LNP. FIG. 5E shows schema of experiment to evaluate pharmacodynamics of LNP delivery of nanoplasmid encoding the splicing regulated mEmerald construct in human cells engrafted in mice. NSG mice were engrafted systemically with U2AF1S34Y / WTK562 cells and then two weeks later, 25 pg of LNP with engrafted systemically twice / week intravenously for 2 weeks. Mice were then sacrificed 24 hours after the last LNP injection and tissues were evaluated for human cells (marked by human CD45 (hCD45)), GFP expression, and LNP uptake (marked by -8- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526APC-Cy7). FIG. 5F shows representative flow cytometry data of mice from (FIG. 5E). FIG. 5G shows % viability of U2AF1WTand U2AF1S34Y / WTK562 cells treated with empty LNP or LNPs encapsulating the indicating synthetic intron regulated HSV-TK vector shown followed by ganciclovir treatment. FIG. 5H shows RT-PCR of HSV-TK in cells treated from FIG. 5G.

[0020] FIG. 6 shows a schematic of U2AF1 synthetic intron cDNA library based on mutagenesis of the MTA1 synthetic intron.

[0021] FIGs. 7A-7C depict LNP delivery of synthetic introns. FIG. 7A provides a schematic of (top) non-targeted mRNA LNP preparation including ionizable lipid (SM- 102), helper lipid, lipid-PEG and cholesterol; as well as (bottom) targeted mRNA LNP conjugated with fab (fragment antigen-binding) region of CD33. FIGs. 7B-7C show flow cytometry of RPMI8226 myeloma tumor cell GFP content following mRNA LNP delivery to CD38+cells in vivo and quantification of mRNA LNP delivery to tumor cells and CD38+cells.

[0022] FIG. 8 provides a schematic of synthetic introns useful to target U2AF1 mutant leukemias and dissect the molecular basis for mis-splicing.

[0023] FIG. 9 provides a summary of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B intron sequences useful in the synthetic intron constructs of the present technology.

[0024] FIG. 10 provides a summary of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B intron sequences with flanking exon sequences useful in the synthetic intron constructs of the present technology.DETAILED DESCRIPTION

[0032] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present technology.

[0033] In practicing the present methods, many conventional techniques in molecular biology, protein biochemistry, cell biology, immunology, microbiology and recombinant DNA are used. See, e.g., Sambrook and Russell eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; the series Ausubel etal. eds. (2007) Current Protocols in -9- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526Molecular Biology, the series Methods in Enzymology (Academic Press, Inc., N. Y.);MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach,' Harlow and Lane eds. ( \999 Antibodies, A Laboratory Manual,' Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th edition; Gait ed. (1984) Oligonucleotide Synthesis,' U.S. Patent No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization,' Anderson (1999) Nucleic Acid Hybridization,' Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al. eds (1996) Weir ’s Handbook of Experimental Immunology. Methods to detect and measure levels of polypeptide gene expression products (i.e., gene translation level) are well-known in the art and include the use of polypeptide detection methods such as antibody detection and quantification techniques. (See also, Strachan & Read, Human Molecular Genetics, Second Edition. (John Wiley and Sons, Inc., NY, 1999)).

[0034] Disclosed herein are methods for harnessing U2AF1 mutation dependent abnormal splicing to drive the mutation specific gene expression to selectively eliminate U2AF1 mutant cancer cells.Definitions

[0035] Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. For example, reference to “a cell” includes a combination of two or more cells, and the like. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, analytical chemistry and nucleic acid chemistry and hybridization described below are those well-known and commonly employed in the art.-10- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0036] As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.

[0037] As used herein, the term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, z.e., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5-fold, or within 2-fold, of a value.

[0038] As used herein, the “administration” of an agent or drug to a subject includes any route of introducing or delivering to a subject a compound to perform its intended function. Administration can be carried out by any suitable route, including but not limited to, orally, intranasally, parenterally (intravenously, intramuscularly, intraperitoneally, or subcutaneously), rectally, intrathecally, intratumorally or topically. Administration includes self-administration and the administration by another.

[0039] The term “amino acid” refers to naturally occurring and non-naturally occurring amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine) and pyrolysine and selenocysteine. Amino acid analogs refer to agents that have the same basic chemical structure as a naturally occurring amino acid, z.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, such as, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (such as, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. In some embodiments, amino acids forming a polypeptide are in the D form. In some embodiments, the amino acids forming a polypeptide are in the L form. In some embodiments, a first plurality of amino acids-11- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526forming a polypeptide are in the D form, and a second plurality of amino acids are in the L form.

[0040] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, are referred to by their commonly accepted single-letter code.

[0041] As used herein, the term “biological sample” means sample material derived from living cells. Biological samples may include tissues, cells, protein or membrane extracts of cells, and biological fluids (e.g., ascites fluid or cerebrospinal fluid (CSF)) isolated from a subject, as well as tissues, cells and fluids present within a subject.Biological samples of the present technology include, but are not limited to, samples taken from breast tissue, renal tissue, the uterine cervix, the endometrium, the head or neck, the gallbladder, parotid tissue, the prostate, the brain, the pituitary gland, kidney tissue, muscle, the esophagus, the stomach, the small intestine, the colon, the liver, the spleen, the pancreas, thyroid tissue, heart tissue, lung tissue, the bladder, adipose tissue, lymph node tissue, the uterus, ovarian tissue, adrenal tissue, testis tissue, the tonsils, thymus, blood, hair, buccal, skin, serum, plasma, CSF, semen, prostate fluid, seminal fluid, urine, feces, sweat, saliva, sputum, mucus, bone marrow, lymph, and tears. Biological samples can also be obtained from biopsies of internal organs or from cancers. Biological samples can be obtained from subjects for diagnosis or research or can be obtained from non-diseased individuals, as controls or for basic research. Samples may be obtained by standard methods including, e.g., venous puncture and surgical biopsy. In certain embodiments, the biological sample is a tissue sample obtained by needle biopsy.

[0042] As used herein, a “cancer” is a disease state characterized by the presence in a subject of cells demonstrating abnormal uncontrolled replication and in some aspects, the term may be used interchangeably with the term “tumor.” The term “cancer or tumor antigen” refers to an antigen known to be associated and expressed in a cancer cell or tumor cell (such as on the cell surface) or tissue, and the term “cancer or tumor targeting antibody” refers to an antibody that targets such an antigen. In some embodiments, the cancer or tumor antigen is not expressed in a non-cancer cell or tissue. In some embodiments, the cancer or tumor antigen is expressed in a non-cancer cell or tissue at a level significantly lower compared to a cancer cell or tissue.-12- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0043] The term “canonical” 3' splice site refers to a splice site whose usage results in preservation of the open reading frame if the intron is inserted into a coding DNA sequence and subsequently spliced, such that no in-frame termination codons are introduced into the coding sequence if the canonical 3' splice site is used during the splicing process. For example, a canonical 3' splice site may lie at the 3' end of an intron, such that insertion of this intron into a coding sequence and subsequent usage of the canonical 3' splice site during splicing results in complete excision of the intron from the mature RNA transcript, thereby preserving the open reading frame. Canonical 3' splice sites are known in the art, which are encompassed by the present disclosure. Exemplary, non-limiting, canonical 3' splice sites encompassed by the present disclosure comprise at least a core sequence of AAG, C AG, GAG, and TAG. The 3 ' splice sites can be longer, however, such as selected from the non-limiting list including AACAG, AATAG, ACCAG, ACTAG, ATCAG, ATTAG, AGCAG, AGTAG, CACAG, CATAG, CCCAG, CCTAG, CTCAG, CTTAG, CGCAG, CGTAG, TACAG, TATAG, TCCAG, TCTAG, TTCAG, TTTAG, TGCAG, TGTAG, GACAG, GATAG, GCCAG, GCTAG, GTCAG, GTTAG, GGCAG, and GGTAG, all of which are encompassed by the present disclosure.

[0044] The term “cryptic” 3' splice site refers to a splice site whose usage results in disruption of the open reading frame if the intron is inserted into a coding DNA sequence and subsequently spliced, such that one or more in-frame termination codons are introduced into the coding sequence if the cryptic 3' splice site is used during the splicing process. For example, a cryptic 3' splice site may lie downstream (or 3') or upstream (or 5') to, the canonical 3' splice site, such that insertion of this intron into a coding sequence and subsequent usage of the cryptic 3' splice site during splicing does not result in complete excision of the intron from the mature RNA transcript, thereby disrupting the open reading frame. Exemplary, non-limiting cryptic 3' splice sites can comprise a sequence selected from AAG, CAG, GAG, TAG, ATG, CTG, GTG, and TTG.

[0045] As used herein, a “cleavable peptide”, which is also referred to as a “cleavable linker,” means a peptide that can be cleaved, for example, by an enzyme. One translated polypeptide comprising such cleavable peptide can produce two final products, therefore, allowing expressing more than one polypeptides from one open reading frame. One example of cleavable peptides is a self-cleaving peptide, such as a 2A self-cleaving peptide.2A self-cleaving peptides, is a class of 18-22 aa-long peptides, which can induce the -13- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526cleaving of the recombinant protein in a cell. In some embodiments, the 2 A self-cleaving peptide is selected from P2A, T2A, E2A, F2A and BmCPV2A. See, for example, Wang Y, et al. Sci Rep. 2015;5: 16273. Published 2015 Nov 5. As used herein, the terms “T2A” and “2A peptide” are used interchangeably to refer to any 2A peptide or fragment thereof, any 2A-like peptide or fragment thereof, or an artificial peptide comprising the requisite amino acids in a relatively short peptide sequence (on the order of 20 amino acids long depending on the virus of origin) containing the consensus polypeptide motif D-V / I-E-X-N-P-G-P (SEQ ID NO:91), wherein X refers to any amino acid generally thought to be self-cleaving.

[0046] As used herein, “complementary” sequences refer to two nucleotide sequences which, when aligned anti-parallel to each other, contain multiple individual nucleotide bases which pair with each other. Paring of nucleotide bases forms hydrogen bonds and thus stabilizes the double strand structure formed by the complementary sequences. It is not necessary for every nucleotide base in two sequences to pair with each other for sequences to be considered “complementary”. Sequences may be considered complementary, for example, if at least 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the nucleotide bases in two sequences pair with each other. In some embodiments, the term complementary refers to 100% of the nucleotide bases in two sequences pair with each other. In addition, sequences may still be considered “complementary” when the total lengths of the two sequences are significantly different from each other. For example, a primer of 15 nucleotides may be considered “complementary” to a longer polynucleotide containing hundreds of nucleotides if multiple individual nucleotide bases of the primer pair with nucleotide bases in the longer polynucleotide when the primer is aligned anti-parallel to a particular region of the longer polynucleotide. Nucleotide bases paring is known in the field, such as in DNA, the purine adenine (A) pairs with the pyrimidine thymine (T) and the pyrimidine cytosine (C) always pairs with the purine guanine (G); while in RNA, adenine (A) pairs with uracil (U) and guanine (G) pairs with cytosine (C). Further, the nucleotide bases aligned anti-parallel to each other in two complementary sequences, but not a pair, are referred to herein as a mismatch.

[0047] As used herein, a "control" is an alternative sample used in an experiment for comparison purpose. A control can be "positive" or "negative." For example, where the purpose of the experiment is to determine a correlation of the efficacy of a therapeutic agent -14- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526for the treatment for a particular type of disease, a positive control (a compound or composition known to exhibit the desired therapeutic effect) and a negative control (a subject or a sample that does not receive the therapy or receives a placebo) are typically employed.

[0048] As used herein, the term “effective amount” refers to a quantity sufficient to achieve a desired therapeutic and / or prophylactic effect, e.g., an amount which results in the prevention of, or a decrease in a disease or condition described herein or one or more signs or symptoms associated with a disease or condition described herein. In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will vary depending on the composition, the degree, type, and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The compositions can also be administered in combination with one or more additional therapeutic compounds. In the methods described herein, the therapeutic compositions may be administered to a subject having one or more signs or symptoms of a disease or condition described herein. As used herein, a "therapeutically effective amount" of a composition refers to composition levels in which the physiological effects of a disease or condition are ameliorated or eliminated. A therapeutically effective amount can be given in one or more administrations.

[0049] As used herein, the term “expression” refers to the process by which polynucleotides are transcribed into mRNA and / or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell. The expression level of a gene can be determined by measuring the amount of mRNA or protein in a cell or tissue sample. In one aspect, the expression level of a gene from one sample can be directly compared to the expression level of that gene from a control or reference sample. In another aspect, the expression level of a gene from one sample can be directly compared to the expression level of that gene from the same sample following administration of the compositions disclosed herein. The term “expression” also refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription) within a cell; (2) processing of an RNA transcript (e.g, by splicing, editing, 5’ cap formation, and / or 3’ end formation) within -15- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526a cell; (3) translation of an RNA sequence into a polypeptide or protein within a cell; (4) post-translational modification of a polypeptide or protein within a cell; (5) presentation of a polypeptide or protein on the cell surface; and (6) secretion or presentation or release of a polypeptide or protein from a cell.

[0050] As used herein, an "expression vector" includes vectors capable of expressing DNA that is operably linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such additional segments can include promoter and terminator sequences, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA.Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and / or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

[0051] As used herein, an “expression control sequence” refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operably linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences.Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence. The term “control sequences” is intended to encompass, at a minimum, any component whose presence is essential for expression, and can also encompass an additional component whose presence is advantageous, for example, leader sequences.-16- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0052] As used herein, the term “gene” means a segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.

[0053] As used herein, a “heterologous nucleic acid sequence” is any nucleic acid sequence placed at a location where it does not normally occur. A heterologous nucleic acid sequence may comprise a sequence that does not naturally occur in a cell, or it may comprise only sequences naturally found in the cell, but placed at a non-normally occurring location in the cell. In some embodiments, the heterologous nucleic acid sequence is not an endogenous sequence. In certain embodiments, the heterologous nucleic acid sequence is an endogenous sequence that is derived from a different cell. In other embodiments, the heterologous nucleic acid sequence is a sequence that occurs naturally in a cell but is then relocated to another site where it does not naturally occur, rendering it a heterologous sequence at that new site. In some embodiments, the nucleic acid molecule is a cDNA, DNA or RNA molecule.

[0054] “Homology” or “identity” or “similarity” refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art. In some embodiments, default parameters are used for alignment. One alignment program is BLAST, using default parameters. In particular, programs are BLASTN and BLASTP, using the following default parameters: Genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by =HIGH SCORE; Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+SwissProtein+SPupdate+PIR. Details of these programs can be found at the National Center for Biotechnology-17- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526Information. Biologically equivalent polynucleotides are those having the specified percent homology and encoding a polypeptide having the same or similar biological activity. Two sequences are deemed “unrelated” or “non-homologous” if they share less than 40% identity, or less than 25% identity, with each other.

[0055] As used herein, a "host cell" is a cell that is used to receive, maintain, reproduce and amplify an expression vector. A host cell also can be used to express the polypeptide encoded by the expression vector. The nucleic acid contained in the expression vector is replicated when the host cell divides, thereby amplifying the nucleic acids. In some embodiments, the host cell as disclosed herein is a eukaryotic cell or a prokaryotic cell. In some embodiments, the host cell is a human cell. In some embodiments, the host cell is a cell line, such as a human embryonic kidney 293 cell (HEK 293 cell or 293 cell), or a 293 T cell. These cells are commercially available, for example, from the American Type Culture Collection (ATCC).

[0056] As used herein, the terms “identical” or percent “identity”, when used in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (z.e., about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region (e.g., nucleotide sequence encoding an antibody described herein or amino acid sequence of an antibody described herein)), when compared and aligned for maximum correspondence over a comparison window or designated region as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (e.g., NCBI web site). Such sequences are then said to be “substantially identical.” This term also refers to, or can be applied to, the complement of a test sequence. The term also includes sequences that have deletions and / or additions, as well as those that have substitutions. In some embodiments, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or 50-100 amino acids or nucleotides in length.

[0057] As used herein, the terms “individual”, “patient”, or “subject” can be an individual organism, a vertebrate, a mammal, or a human. In some embodiments, the individual, patient or subject is a human.-18- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0058] As used herein, the term “linker” refers to any amino acid sequence comprising from a total of 1 to 200 amino acid residues; or about 1 to 10 amino acid residues, or alternatively 8 amino acids, or alternatively 6 amino acids, or alternatively 5 amino acids that may be repeated from 1 to 10, or alternatively to about 8, or alternatively to about 6, or alternatively to about 5, or alternatively, to about 4, or alternatively to about 3, or alternatively to about 2 times. For example, the linker may comprise up to 15 amino acid residues consisting of a pentapeptide repeated three times. In one embodiment, the linker sequence is a (G4S)n (SEQ ID NO: 92), wherein n is 1, or 2, or 3, or 4, or 5, or 6, or 7, or 8, or 9, or 10, or 11, or 12, or 13, or 14, or 15.

[0059] As used herein, “operably linked” means that expression control sequences are positioned relative to a nucleic acid of interest to initiate, regulate or otherwise control transcription of the nucleic acid of interest. For example, a nucleic acid encoding a leader peptide can be operably linked to a nucleic acid encoding a polypeptide, whereby the nucleic acids can be transcribed and translated to express a functional fusion protein, wherein the leader peptide affects secretion of the fusion polypeptide. In some instances, the nucleic acid encoding a first polypeptide (e.g., a leader peptide) is operably linked to nucleic acid encoding a second polypeptide and the nucleic acids are transcribed as a single mRNA transcript, but translation of the mRNA transcript can result in one of two polypeptides being expressed. For example, an amber stop codon can be located between the nucleic acid encoding the first polypeptide and the nucleic acid encoding the second polypeptide, such that, when introduced into a partial amber suppressor cell, the resulting single mRNA transcript can be translated to produce either a fusion protein containing the first and second polypeptides, or can be translated to produce only the first polypeptide. In another example, a promoter can be operably linked to nucleic acid encoding a polypeptide, whereby the promoter regulates or mediates the transcription of the nucleic acid.

[0060] As used herein, the “percent homology” between two amino acid sequences is equivalent to the percent identity between the two sequences. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences ( / .< ., % homology = # of identical positions / total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.-19- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0061] The percent homology between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 1 1-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent homology between two amino acid sequences can be determined using the Needleman and Wunsch (J Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

[0062] Additionally or alternatively, the amino acids sequences of the presently disclosed subject matter can further be used as a “query sequence” to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul, et al. (1990) J. Mol. Biol.215 :403-10. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the specified sequences disclosed herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res.25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0063] As used herein, the term “pharmaceutically-acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, and the like, compatible with pharmaceutical administration. Pharmaceutically-acceptable carriers and their formulations are known to one skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences (20thedition, ed. A. Gennaro, 2000, Lippincott, Williams & Wilkins, Philadelphia, Pa.).

[0064] As used herein, the term “polynucleotide” or “nucleic acid” means any RNA or DNA, which may be unmodified or modified RNA or DNA. Polynucleotides include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, RNA that is mixture of single-and double-stranded regions, and hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double- -20- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526stranded regions. In addition, polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

[0065] Polynucleotides having “substantial homology” or “substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule. By “hybridize” is meant pair to form a doublestranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger , Methods Enzymol. 152:399 (1987); Kimmel, A. IE Methods Enzymol. 152:507 (1987)). For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, less than about 500 mM NaCl and 50 mM trisodium citrate, or less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% w / v formamide, or at least about 50% w / v formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, at least about 37°C, or at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In certain embodiments, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% w / v SDS. In certain embodiments, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% w / v SDS, 35% w / v formamide, and 100 pg / ml denatured salmon sperm DNA (ssDNA). In certain embodiments, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% w / v SDS, 50% w / v formamide, and 200 pg ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

[0066] For most applications, washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps -21- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526will less than about 30 mM NaCl and 3 mM trisodium citrate, or less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25°C, at least about 42°C, or at least about 68°C. In certain embodiments, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% w / v SDS. In certain embodiments, wash steps will occur at 42°C in 15 mMNaCl, 1.5 mM trisodium citrate, and 0.1% w / v SDS. In certain embodiments, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% w / v SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196: 180 (1977)); Grunstein and Rogness (Proc. Natl. Acad. Sci., USA 72:3961 (1975)); Ausubel etal. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook etal., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

[0067] As used herein, the terms “polypeptide”, “peptide” and “protein” are used interchangeably herein to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. Polypeptide refers to both short chains, commonly referred to as peptides, glycopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.

[0068] As used herein, “prevention” or “preventing” of a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset of one or more symptoms of the disorder or condition relative to the untreated control sample.

[0069] As used herein, the term “promoter” refers to an expression control sequence that can activate transcription (expression) of a gene. As indicated, a promoter is typically located upstream of a gene, but can be located at other regions proximal to the gene, or even -22- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526within the gene. The promoter typically contains binding sites for RNA polymerase and one or more transcription factors, which participate in the assembly of the transcriptional complex.

[0070] As used herein, the term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the material is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

[0071] As used herein, the term “separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.

[0072] As used herein, the term “sequential” therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes, hours, or days before administering the other active ingredient or ingredients. There is no simultaneous treatment in this case.

[0073] As used herein, the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.

[0074] As used herein, the term “synthetic” refers to the sequence of the construct (e.g., including the intron sequence and a heterologous promoter), which does not occur in nature, but has been generated or derived from a naturally occurring sequence.

[0075] As used herein, the term “therapeutic agent” is intended to mean a compound that, when present in an effective amount, produces a desired therapeutic effect on a subject in need thereof.-23- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0076] “Treating” or “treatment” as used herein covers the treatment of a disease or disorder described herein, in a subject, such as a human, and includes: (i) inhibiting a disease or disorder, z.e., arresting its development; (ii) relieving a disease or disorder, z.e., causing regression of the disorder; (iii) slowing progression of the disorder; and / or (iv) inhibiting, relieving, or slowing progression of one or more symptoms of the disease or disorder. In some embodiments, treatment means that the symptoms associated with the disease are, e.g., alleviated, reduced, cured, or placed in a state of remission.

[0077] It is also to be appreciated that the various modes of treatment or prevention of disorders as described herein are intended to mean “substantial,” which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved. The treatment may be a continuous prolonged treatment for a chronic disease or a single, or few time administrations for the treatment of an acute condition.RNA Splicing Factor Mutations are Common in Myeloid Leukemias and Confer Change-of-function Activity

[0078] Recurrent somatic mutations in genes encoding components of the splicing machinery are the most common class of genetic alterations in patients with myelodysplastic syndromes (MDS) and additionally highly recurrent prevalent in patients with all forms of myeloid leukemias and chronic lymphocytic leukemia.1'5These “spliceosomal mutations” primarily affect four proteins: SF3B1, SRSF2, U2AF1, and ZRSR2.

[0079] Spliceosomal mutations alter splice site and exon recognition to cause dramatic mis-splicing of a restricted set of genes while leaving most genes unaffected. Studies6'8have identified that the most common spliceosomal mutations alter RNA recognition in a sequence-specific manner to cause widespread RNA mis-splicing of many genes in a manner distinct from loss of function. For example, U2AF1 is a core component of the spliceosome and heterodimerizes with U2AF2 to recognize the 3’ splice site within intronic pre-mRNA. MDS -associated mutations affecting U2AF1 mutations occur as heterozygous missense mutations at Serine 34 or Glutamine 157 within UZAFl’s zing fingers and change the preferred 3’ splice site in cells bearing these mutations in a reproducible manner based on the identity of the nucleotides surrounding the AG dinucleotides which demarcate the 3’ splice site9,10. In contrast to these sequence-specific changes in exon and splice site-24- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526recognition, deletion of U2AF1 results in splicing failure characterized by widespread cassette exon skipping and intron retention.MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B Synthetic Intron Constructs of the Present Technology

[0080] As used herein, the term “upstream” refers to a position in a nucleic acid molecule or sequence that is on the 5' side of the reference position within the nucleic acid molecule or sequence. Conversely, the term “downstream” refers to a position in a nucleic acid molecule or sequence that is on the 3' side of the reference position within the nucleic acid molecule or sequence.

[0081] In one aspect, the present disclosure provides a synthetic intron construct comprising (a) a heterologous promoter and (b) an intron domain derived from a naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B, wherein the heterologous promoter is located upstream of the intron domain. In some embodiments of the synthetic intron construct disclosed herein, the intron domain comprises (i) a 5' splice site, (ii) a canonical 3' splice site, and (iii) at least one cryptic 3' splice site. Additionally or alternatively, in certain embodiments of the synthetic intron construct disclosed herein, the intron domain further comprises a pyrimidine-rich domain comprising at least 6 consecutive nucleotides; and / or at least one branchpoint at least 15 nucleotides upstream of the canonical 3' splice site.

[0082] The intron domain may comprise any functional 5' splice site sequence that is typically recognized by splicing factors. 5' splice sites are known in the art and are encompassed by the present disclosure. Exemplary, non-limiting 5' splice sites include, but are not limited to, GTGAG, GTAAG, GTGCG, GTACG, GTGGG, GTAGG, GTGTG, GTATG, and GTATC. As known to a person of ordinary skill in the art, the 5' splice site is by definition positioned upstream, or 5' to, the other recited elements of the intron domain. Additionally or alternatively, in certain embodiments of the synthetic intron construct disclosed herein, the at least one cryptic 3' splice site is positioned within about 150 nucleotides (e.g., including within about 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10 nucleotides or any range therein) upstream of the canonical 3' splice site or within about 150 nucleotides (e.g., including within about 140, 130, 120, 110, 100, 90, 80, 70, 60,-25- 4904-0631-6176.1Atty. Dkt. No.: 115872-352650, 40, 30, 20, 10 nucleotides, or any range therein) downstream of the canonical 3' splice site.

[0083] The intron domain can comprise a plurality (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) of cryptic 3' splice sites, which can be the same or different from each other. For example, each of the plurality of the cryptic 3' splice sites can comprise a sequence independently selected from AAG, CAG, GAG, TAG, ATG, CTG, GTG, and TTG. In some embodiments of the synthetic intron construct disclosed herein, the intron domain comprises a plurality of cryptic 3' splice sites within about 150 nucleotides (e.g., including within about 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10 nucleotides or any range therein) upstream of the 3' canonical splice site. In certain embodiments of the synthetic intron construct disclosed herein, the intron domain comprises a plurality of cryptic 3' splice sites within about 150 nucleotides (e.g., including within about 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10 nucleotides or any range therein) downstream of the 3' canonical splice site. Additionally or alternatively, in some embodiments of the synthetic intron construct disclosed herein, the intron domain comprises one or more cryptic 3' splice sites within about 150 nucleotides (e.g., including within about 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10 nucleotides or any range therein) upstream of the 3' canonical splice site and one or more cryptic 3' splice sites within about 100 nucleotides (e.g., including within about 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10 nucleotides or any range therein) downstream of the 3' canonical splice site.

[0084] The sequence of the pyrimidine-rich domain is a contiguous sequence that is at least about 60% pyrimidine nucleotides (e.g, including at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, and 95% pyrimidine nucleotides). Examples of pyrimidine nucleotides are cytosine, thymine, and uracil, although the disclosure also encompasses non-canonical derivatives and analogs thereof that preserve the pyrimidine core structure. The pyrimidine-rich domain is positioned within at least about 80 nucleotides of a cryptic 3' splice site (e.g., including within about 70, 60, 50, 40, 30, 20, 10 nucleotides, or any range therein). As used in this context, the reference to the distance, or range of distances, between the pyrimidine-rich domain and the cryptic 3' splice site refers to the number of intervening nucleotides between and including the closest nucleotide of the pyrimidine-rich domain and the cryptic 3' splice site. Thus, a portion of the pyrimidine-rich domain (including a substantial-26- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526portion) can be outside the indicated range. The pyrimidine-rich domain can be located upstream or downstream of the cryptic 3' splice site.

[0085] In some embodiments of the synthetic intron construct disclosed herein, the pyrimidine-rich domain comprises at least 15 consecutive nucleotides, such as about 15, 20, 25, 30, 35, 40, 45, 50, or more nucleotides. In some embodiments of the synthetic intron construct disclosed herein, the pyrimidine-rich domain has a sequence with at least 60% pyrimidine nucleotides (e.g., including at least about 60% 65%, 70%, 75%, 80%, 85%, 90%, and 95% pyrimidine nucleotides) and is also at least 40% thymine nucleotides (e.g., including at least about 45%, 50%, 55%, 60% 65%, 70%, 75%, 80%, 85%, and 90% thymine nucleotides), which contribute to the pyrimidine proportion indicated above. In some embodiments of the synthetic intron construct disclosed herein, the pyrimidine-rich domain is within at least 30 nucleotides (e.g., including within about 25, 20, 10 nucleotides, or any range therein) of a cryptic 3' splice site. As indicated above, the expression of proximity to the splice site refers to the number of intervening nucleotides between and including the closest nucleotide of the pyrimidine-rich domain and the cryptic 3' splice site. In some embodiments of the synthetic intron construct disclosed herein, the pyrimidine-rich domain comprises two, three, four, or more of the elements described in this paragraph, in any combination.

[0086] As indicated above, the intron domain comprises at least one branchpoint at least 15 nucleotides upstream of the canonical 3' splice site. A branchpoint is a nucleotide that participates in a specific step during splicing catalysis. RNA splicing generally proceeds via a two-step process defined by sequential transesterification reactions between three nucleotides: the first nucleotide of the 5' splice site, the branch nucleotide (branchpoint) upstream of the 3' splice site, and the last nucleotide of the 3' splice site. In the first step of splicing, the 2' OH group of the branchpoint engages in a nucleophilic attack on the phosphate between the upstream exon and the 5' splice site, forming a 2'-5 ' phosphodiester linkage (the “branch”) characteristic of the lariat RNA intermediate and releasing the upstream exon. The 3' OH group of the now-free upstream exon then engages in a nucleophilic attack on the phosphate between the 3' splice site and the downstream exon, resulting in release of the intronic lariat and exon ligation (for review, see Wahl et al., The Spliceosome: Design Principles of a Dynamic RNP Machine, Cell, 2009, 136(4):701 -718, incorporated herein by reference in its entirety). The intronic lariat is then linearized via -27- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526debranching and subsequently degraded. In some embodiments of the synthetic intron construct disclosed herein, the at least one branchpoint is at least 20 nucleotides upstream of the canonical 3' splice site, and wherein the branchpoint nucleotide is an adenine. In some embodiments of the synthetic intron construct disclosed herein, the branchpoint and surrounding sequence context has sequence identity of at least 50% to the sequence tactaAca, where the nucleotide represented by the uppercase A is the branchpoint nucleotide and is preserved in the sequence. Other branchpoint nucleotides and surrounding sequence contexts are known in the art and are encompassed by the present disclosure.

[0087] Intron lengths can vary widely in natural settings and still be functionally spliced to result in a contiguous coding sequence in mature RNA transcripts. For example, typical intron lengths in the human genome can be approximately 6,400 nucleotides. Accordingly, the disclosed intron domain is not limited by length. In some embodiments of the synthetic intron construct disclosed herein, the intron domain is at least about 50 nucleotides to about 1500 nucleotides, such as at least about 50 nucleotides to about 1250 nucleotides, about 50 nucleotides to about 1000 nucleotides, about 50 nucleotides to about 900 nucleotides, about 50 nucleotides to about 800 nucleotides, about 50 nucleotides to about 700 nucleotides, about 50 nucleotides to about 600 nucleotides, about 50 nucleotides to about 500 nucleotides, about 100 nucleotides to about 1500 nucleotides, about 100 nucleotides to about 1250 nucleotides, about 100 nucleotides to about 1000 nucleotides, about 100 nucleotides to about 900 nucleotides, about 100 nucleotides to about 800 nucleotides, about 100 nucleotides to about 700 nucleotides, about 100 nucleotides to about 600 nucleotides, about 100 nucleotides to about 500 nucleotides, and any length or range therein. In some embodiments of the synthetic intron construct disclosed herein, the intron domain is about 200-600 nucleotides in length.

[0088] Additionally or alternatively, in some embodiments of the synthetic intron construct disclosed herein, the intron domain comprises a sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to a sequence derived from the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B. The sequence derived from the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B can be, e.g., at least about 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, or more contiguous nucleotides in length. In some -28- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526embodiments of the synthetic intron construct disclosed herein, the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B is a human wildtype intron of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B. Exemplary naturally occurring intron sequences include intron 13 of MTA1, intron 6 of TRMT13, intron 2 of PRUNE 1, intron 6 of POLB, intron 4 of RNF216, or intron 4 of DNMT3B.

[0089] The synthetic intron constructs of the present technology may comprise the intron domain in addition to coding sequences flanking one or both ends. In one embodiment, the synthetic intron construct further comprises a first exon domain and a second exon domain, wherein the intron domain is inserted between the first exon domain and the second exon domain. Upon proper splicing, the combination of the first exon domain and the second exon domain in a contiguous sequence, i.e., without the intron) encodes part or all of a protein of interest. Additionally or alternatively, in certain embodiments of the synthetic intron construct disclosed herein, the intron domain derived from the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B is flanked by upstream and downstream exon sequences. Exemplary synthetic intron constructs include intron 13 of MTA1 flanked by exon 13 and exon 14, intron 6 of TRMT13 flanked by exon 6 and exon 7, intron 2 of PRUNE 1 flanked by exon 2 and exon 3, intron 6 of POLB flanked by exon 6 and exon 7, intron 4 of RNF216 flanked by exon 4 and exon 5, or intron 4 of DNMT3B flanked by exon 4 and exon 5. Additionally or alternatively, in some embodiments of the synthetic intron construct disclosed herein, the intron domain comprises the sequence of any one of SEQ ID NOs: 1-42. See FIG. 9.Additionally or alternatively, in certain embodiments, the synthetic intron construct comprises the sequence of any one of SEQ ID NOs: 1-90 (FIG. 10) or a sequence that is at least 70% identical to the sequence of any one of SEQ ID NOs: 1-90.

[0090] The embodiments of the synthetic intron construct described herein, including those described above, are configured to be spliced differently in a cell (e.g., cancer cell) comprising a mutation in U2AF1. The difference in splicing is relative to the splicing pattern of the intron in a cell lacking a mutation in U2AF1. In some embodiments, the synthetic intron construct is more likely to be recognized and spliced in a cell comprising a mutation in U2AF1 compared to in a cell without the mutation. In some embodiments, the synthetic intron construct is less likely to be recognized and spliced in a cell comprising a mutation in U2AF1 compared to in a cell without the mutation. In some embodiments, the -29- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526synthetic intron construct is preferentially partially spliced out in a cell comprising a mutation in U2AF1, such that a portion of the intron is not excised from the mature transcript, while the entire intron is preferentially spliced out in a cell without the mutation. In some embodiments, the entire intron is preferentially spliced out in a cell comprising a mutation in U2AF1, while the intron is partially spliced out in a cell without the mutation, such that a portion of the intron is not excised from the mature transcript. Additionally or alternatively, in some embodiments, the mutation in U2AF1 is a Serine 34 mutation or a Glutamine 157 mutation within U2AF1. In certain embodiments, the Serine 34 mutation or Glutamine 157 mutation within U2AF1 is S34F or S34Y.

[0091] In any of the preceding embodiments, the synthetic intron construct of the present technology further comprises a suicide gene and / or a fluorescent protein. The intron domain is inserted between a first exon domain of the suicide gene and a second exon domain of the suicide gene. Additionally or alternatively, in some embodiments of the synthetic intron construct described herein, the suicide gene is herpes simplex virus thymidine kinase (HSV-TK) or inducible caspase 9 (iCasp9). Examples of fluorescent proteins include, but are not limited to, TagBFP, Azurite, EBFP2, mKalamal, Sirius, Sapphire, T-Sapphire, ECFP, Cerulean, SCFP3 A, mTurquoise, monomeric Midoriishi-Cyan, TagCFP, mTFPl, EGFP, Emerald, Superfolder GFP, Monomeric Azami Green, TagGFP2, mUKG, mWasabi, EYFP, Citrine, Venus, SYFP2, TagYFP, Monomeric Kusabira-Orange, mKOK, mK02, mOrange, mOrange2, mRaspberry, mCherry, dsRed, mStrawberry, mTangerine, tdTomato, TagRFP, TagRFP-T, mApple, mRuby, mPlum, HcRed-Tandem, mKate2, mNeptune, NirFP, TagRFP657, IFP1.4, iRFP, mKeimaRed, LSS-mKatel, LSS-mKate2, PA-GFP, PAmCherryl, PATagRFP, Kaede (green), Kaede (red), KikGRl (green), KikGRl (red), PS-CFP2, PS-CFP2, mEos2 (green), mEos2 (red), PSmOrange, or Dronpa. Additionally or alternatively, in some embodiments of the synthetic intron construct described herein, the fluorescent protein is located downstream of the intron domain.

[0092] In any of the foregoing embodiments, the synthetic intron construct of the present technology further comprises a cytokine. Examples of cytokines include, but are not limited to, interferon a, interferon P, interferon y, complement C5a, IL-2, TNF alpha, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL19, CCL2, CCL20,-30- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2. In certain embodiments, the intron domain and the cytokine are separated by a cleavable linker. In some embodiments, the cleavable linker is a 2A self-cleaving peptide linker selected from the group consisting of P2A, T2A, E2A, F2A and BmCPV2A.

[0093] The heterologous promoter can be constitutive or inducible. Constitutive promoters can be determined based on the character of the target cell and the particular transcription factors available in the cytosol. A person of ordinary skill in the art can select an appropriate promoter based on the intended use, as various promoters are known and commonly used in the art.Vectors

[0094] Many expression vectors are available and known to those of skill in the art and can be used for nonendogenous expression of the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein. The choice of expression vector will be influenced by the choice of host expression system. Such selection is well within the level of skill of the skilled artisan. In general, expression vectors can include transcriptional promoters and optionally enhancers, translational signals, and transcriptional and translational termination signals. Expression vectors that are used for stable transformation typically have a selectable marker which allows selection and maintenance of the transformed cells. In some cases, an origin of replication can be used to amplify the copy number of the vector in the cells.

[0095] Vectors also can contain additional nucleotide sequences operably linked to the ligated nucleic acid molecule, such as, for example, an epitope tag such as for localization, e.g., a hexa-his tag or a myc tag, hemagglutinin tag or a tag for purification, for example, a GST fusion, and a sequence for directing protein secretion and / or membrane association.

[0096] Expression of the heterologous MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein can be controlled by any-31- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526promoter / enhancer known in the art. Suitable bacterial promoters are well known in the art and described herein below. Other suitable promoters for mammalian cells, yeast cells and insect cells are well known in the art and some are exemplified below. Selection of the promoter used to direct expression of a heterologous nucleic acid depends on the particular application and is within the level of skill of the skilled artisan. Promoters which can be used include but are not limited to eukaryotic expression vectors containing the SV40 early promoter (Bemoist and Chambon, Nature 290:304-310(1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto etal., Cell 22:787-797(1980)), the herpes thymidine kinase promoter (Wagner etal., Proc. Natl. Acad. Sci. USA I '. 1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., Nature 296:39-42 (1982)); prokaryotic expression vectors such as the P-lactamase promoter (Jay et al., Proc. Natl. Acad. Sci. USA 75:5543 (1981)) or the tac promoter (DeBoer etal., Proc. Natl. Acad. Sci. USA 50:21-25(1983)); see also "Useful Proteins from Recombinant Bacteria": in Scientific American 242:79-94 (1980)); plant expression vectors containing the nopaline synthetase promoter (Herrera- Estrella et al., Nature 505:209-213(1984)) or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., Nucleic Acids Res. 9:2871(1981)), and the promoter of the photosynthetic enzyme ribulose bisphosphate carboxylase (Herrera-Estrella et al., Nature 510: 1 15-120(1984)); promoter elements from yeast and other fungi such as the Gal4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase (PGK) promoter, the alkaline phosphatase promoter, and the following animal transcriptional control regions that exhibit tissue specificity and have been used in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., Cell 55:639-646 (1984); Ornitz et al., Cold Spring Harbor Symp. Quant. Biol. 50:399-409(1986); MacDonald, Hepatology 7:425-515 (1987)); insulin gene control region which is active in pancreatic beta cells (Hanahan et al., Nature 515: 115-122 (1985)), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., Cell 55:647-658 (1984); Adams et al., Nature 515:533-538 (1985); Alexander et al., Mol. Cell Biol. 7: 1436-1444 (1987)), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., Cell 15:485-495 (1986)), albumin gene control region which is active in liver (Pinckert et al., Genes andDevel. 1:268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., Mol. Cell. Biol. 5: 1639-403 (1985)); Hammer et al., Science-32- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526255:53-58 (1987)), alpha-1 antitrypsin gene control region which is active in liver (Kelsey etal., Genes and Devel. 7:161-171 (1987)), beta globin gene control region which is active in myeloid cells (Magram et al., Nature 515:338-340 (1985)); Kollias et al., Cell 5:89-94 (1986)), myelin basic protein gene control region which is active in oligodendrocyte cells of the brain (Readhead et al., Cell 15:703-712 (1987)), myosin light chain-2 gene control region which is active in skeletal muscle (Shani, Nature 514:283-286 (1985)), and gonadotrophic releasing hormone gene control region which is active in gonadotrophs of the hypothalamus (Mason etal., Science 254: 1372- 1378 (1986)).

[0097] In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of an antibody, or antigen binding fragment thereof, in host cells. A typical expression cassette contains a promoter operably linked to the nucleic acid sequence encoding the polypeptide chains of interest and signals required for efficient polyadenylation of the transcript, ribosome binding sites and translation termination.Additional elements of the cassette can include enhancers. In addition, the cassette typically contains a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region can be obtained from the same gene as the promoter sequence or can be obtained from different genes.

[0098] Some expression systems have markers that provide gene amplification such as thymidine kinase and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a nucleic acid sequence encoding a germline antibody chain under the direction of the polyhedron promoter or other strong baculovirus promoter.

[0099] Any methods known to those of skill in the art for the insertion of DNA fragments into a vector can be used to construct expression vectors containing a nucleic acid encoding any of the polypeptides provided herein. These methods can include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. If the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules can be enzymatically modified.Alternatively, any site desired can be produced by ligating nucleotide sequences (linkers) -33- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526onto the DNA termini; these ligated linkers can contain specific chemically synthesized nucleic acids encoding restriction endonuclease recognition sequences.

[0100] Exemplary plasmid vectors useful to produce the polypeptides provided herein contain a strong promoter, such as the HCMV immediate early enhancer / promoter or the MHC class I promoter, an intron to enhance processing of the transcript, such as the HCMV immediate early gene intron A, and a polyadenylation (poly A) signal, such as the late SV40 poly A signal.

[0101] The vector can be a retroviral vector (e.g., gamma retroviral), which is employed for the introduction of the DNA or RNA construct into the host cell genome. For example, a polynucleotide encoding the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein can be cloned into a retroviral vector and expression can be driven from its endogenous promoter, from the retroviral long terminal repeat, or from an alternative internal promoter.

[0102] Non-viral vectors or RNA may be used as well. Random chromosomal integration, or targeted integration (e.g, using a nuclease, transcription activator-like effector nucleases (TALENs), Zinc-finger nucleases (ZFNs), and / or clustered regularly interspaced short palindromic repeats (CRISPRs), or transgene expression (e.g, using a natural or chemically modified RNA) can be used.

[0103] For initial genetic modification of the cells to provide cells expressing the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein, a retroviral vector can be employed for transduction. However, any other suitable viral vector or non-viral delivery system can be used for genetic modification of cells. Combinations of retroviral vector and an appropriate packaging line are also suitable, where the capsid proteins will be functional for infecting human cells. Various amphotropic virus-producing cell lines are known, including, but not limited to, PA12 (Miller et al. (1985) Mol. Cell. Biol. 5:431-437); PA317 (Miller et al. (1986) Mol. Cell. Biol. 6:2895-2902); and CRIP (Danos et al. (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464). Non -amphotropic particles are suitable too, e.g., particles pseudotyped with VSVG, RD114 or GALV envelope and any other known in the art.

[0104] Possible methods of transduction also include direct co-culture of the cells with producer cells, e.g., by the method of Bregni, et al, Blood 80: 1418-1422(1992), or-34- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526culturing with viral supernatant alone or concentrated vector stocks with or without appropriate growth factors and poly cations, e.g., by the method of Xu, et al. , Exp. Hemat.22:223-230 (1994); and Hughes, et al., J. Clin. Invest. 89: 1817 (1992).

[0105] In some embodiments, the chosen vector exhibits high efficiency of infection and stable integration and expression (see, e.g., Cayouette et al., Human Gene Therapy 8:423-430 (1997); Kido c / a / ., Current Eye Research 15:833-844 (1996); Bloomer etal., Journal of Virology 71 :6641-6649, 1997; Naldini et al., Science 272:263 267 (1996); and Miyoshi et al., Proc. Natl. Acad. Sci. U.S.A. 94: 10319, (1997)). Other viral vectors that can be used include, for example, adenoviral, lentiviral, and adeno-associated viral vectors, vaccinia virus, a bovine papilloma virus, or a herpes virus, such as Epstein-Barr Virus (also see, for example, the vectors of Miller, Human Gene Therapy 15-14, (1990); Friedman, Science 244: 1275-1281 (1989); Eglitis et al., BioTechniques 6:608-614, (1988); Tolstoshev et al., Current Opinion in Biotechnology 1:55-61(1990); Sharp, The Lancet 337 : 1277-1278 (1991); Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322 (1987); Anderson, Science 226:401-409 (1984); Moen, Blood Cells 17:407-416 (1991); Miller et al., Biotechnology 7:980-990 (1989); Le Gal La Salle et al., Science 259:988-990 (1993); and Johnson, Chest 107:77S-83S (1995)). Retroviral vectors are particularly well developed and have been used in clinical settings (Rosenberg et al., N. Engl. J. Med 323:370 (1990); Anderson etal., U.S. Pat. No. 5,399,346).

[0106] In certain non-limiting embodiments, the vector expressing the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein is a retroviral vector, e.g., an oncoretroviral vector. In some instances, the retroviral vector is a SFG retroviral vector or murine stem cell virus (MSCV) retroviral vector. In certain non-limiting embodiments, the vector expressing the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein is a lentiviral vector. In certain non-limiting embodiments, the vector expressing the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein is a transposon vector.

[0107] Non-viral approaches can also be employed for the expression of a protein in a cell. For example, a nucleic acid molecule can be introduced into a cell by administering the nucleic acid in the presence of lipofection (Feigner et al., Proc. Nat'l. Acad. Sci. U.S.A.84:7413, (1987); Ono et al., Neuroscience Letters 17:259 (1990); Brigham etal., Am. J.-35- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526Med. Sci. 298:278, (1989); Staubinger et al., Methods in Enzymology 101 :512 (1983)), asialoorosomucoid-polylysine conjugation (Wu et al., Journal of Biological Chemistry 263 : 14621 (1988); Wu et al., Journal of Biological Chemistry 264: 16985 (1989)), or by microinjection under surgical conditions (Wolff et al., Science 247: 1465 (1990)). Other non-viral means for gene transfer include transfection in vitro using calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes can also be potentially beneficial for delivery of DNA into a cell. Transplantation of normal genes into the affected tissues of a subject can also be accomplished by transferring a normal nucleic acid into a cultivatable cell type ex vivo (e.g., an autologous or heterologous primary cell or progeny thereof), after which the cell (or its descendants) are injected into a targeted tissue or are injected systemically. Recombinant receptors can also be derived or obtained using transposases or targeted nucleases (e.g., Zinc finger nucleases, meganucleases, or TALE nucleases). Transient expression may be obtained by RNA electroporation.

[0108] cDNA expression for use in polynucleotide therapy methods can be directed from any suitable promoter (e.g., the human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoters), and regulated by any appropriate mammalian regulatory element or intron (e.g., the elongation factor la enhancer / promoter / intron structure). For example, if desired, enhancers known to preferentially direct gene expression in specific cell types can be used to direct the expression of a nucleic acid. The enhancers used can include, without limitation, those that are characterized as tissue- or cell-specific enhancers. Alternatively, if a genomic clone is used as a therapeutic construct, regulation can be mediated by the cognate regulatory sequences or, if desired, by regulatory sequences derived from a heterologous source, including any of the promoters or regulatory elements described above.

[0109] The resulting cells can be grown under conditions similar to those for unmodified cells, whereby the modified cells can be expanded and used for a variety of purposes. In some embodiments, a vector as disclosed herein further comprises a regulatory sequence directing the expression of the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs described herein.-36- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526Formulations

[0110] MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs disclosed herein and compositions comprising the same can be conveniently provided as sterile liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous compositions, which may be buffered to a selected pH. Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by injection. Viscous compositions, on the other hand, can be formulated within the appropriate viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof.

[0111] Sterile injectable solutions can be prepared by incorporating the compositions of the presently disclosed subject matter, e.g., a composition comprising MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs, in the required amount of the appropriate solvent with various amounts of the other ingredients, as desired. Such compositions may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, dextrose, or the like. The compositions can also be lyophilized. The compositions can contain auxiliary substances such as wetting, dispersing, or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as “REMINGTON' S PHARMACEUTICAL SCIENCE”, 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.

[0112] Various additives which enhance the stability and sterility of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.-37- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526According to the presently disclosed subject matter, however, any vehicle, diluent, or additive used would have to be compatible with the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs of the presently disclosed subject matter.

[0113] The compositions can be isotonic, / .< ., they can have the same osmotic pressure as blood and lacrimal fluid. The desired isotonicity of the compositions of the presently disclosed subject matter may be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is suitable particularly for buffers containing sodium ions.

[0114] Viscosity of the compositions, if desired, can be maintained at the selected level using a pharmaceutically acceptable thickening agent. Methylcellulose can be used because it is readily and economically available and is easy to work with. Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The concentration of the thickener can depend upon the agent selected. The important point is to use an amount that will achieve the selected viscosity. Obviously, the choice of suitable carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form, e.g., liquid dosage form (e.g., whether the composition is to be formulated into a solution, a suspension, gel or another liquid form, such as a time release form or liquid-filled form).

[0115] Those skilled in the art will recognize that the components of the compositions should be selected to be chemically inert and will not affect the viability or efficacy of the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs as described in the presently disclosed subject matter. This will present no problem to those skilled in chemical and pharmaceutical principles, or problems can be readily avoided by reference to standard texts or by simple experiments (not involving undue experimentation), from this disclosure and the documents cited herein.

[0116] For any composition to be administered to an animal or human, and for any particular method of administration, toxicity should be determined, such as by determining the lethal dose (LD) and LD50 in a suitable animal model e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable response. Such determinations do-38- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526not require undue experimentation from the knowledge of the skilled artisan, this disclosure and the documents cited herein. And, the time for sequential administrations can be ascertained without undue experimentation.Uses of the Synthetic Introns of the Present Technology

[0117] In one aspect, the present disclosure provides a method for treating a U2AF1 mutant cancer in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the synthetic intron constructs described herein. The U2AF1 mutant cancer may be selected from among myelodysplastic syndromes (MDS), myeloid cancer (e.g., AML), lung cancer, and pancreatic cancer.

[0118] In another aspect, the present disclosure provides a method for identifying a drug candidate that inhibits mis-splicing in a U2AF1 mutant cancer cell comprising contacting the U2AF1 mutant cancer cell with an effective amount of any and all embodiments of the synthetic intron constructs described herein, contacting the U2AF1 mutant cancer cell with a drug candidate, and measuring proliferation of the U2AF1 mutant cancer cell. In some embodiments, the method further comprises determining that the drug candidate is effective when the proliferation of the U2AF1 mutant cancer cell is increased in the presence of the drug candidate compared to the U2AF1 mutant cancer cell without the drug candidate. Additionally or alternatively, in some embodiments, the drug candidate is a small molecule or an inhibitory RNA (e.g., siRNA, shRNA, sgRNA or antisense).

[0119] Additionally or alternatively, in some embodiments of the methods disclosed herein, the synthetic intron construct is administered orally, intranasally, parenterally, intravenously, intramuscularly, intraperitoneally, or subcutaneously, rectally, intrathecally, intratumorally or topically. In certain embodiments of the methods disclosed herein, the synthetic intron construct is formulated with a lipid nanoparticle (LNP). The LNP may comprise a receptor that targets the U2AF1 mutant cancer cell. In some embodiments, the receptor is a Fab, a Fab’, a scFv, or a (Fab)2. Additionally or alternatively, in some embodiments of the methods disclosed herein, the receptor targets a ligand expressed on the cell surface of the U2AF1 mutant cancer cell.Combination Therapy

[0120] The compositions of the present technology may be employed in conjunction with other therapeutic agents useful in the treatment of U2AF1 -mutant cancers. For -39- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526example, MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs of the present technology may be separately, sequentially or simultaneously administered with at least one additional cancer therapy. In some embodiments, the additional cancer therapy is selected from among a chemotherapy, a radiation therapy, an immunotherapy, a monoclonal antibody, an anti-cancer nucleic acid, an anti-cancer protein, an anti-cancer virus or microorganism, a cytokine, or any combination thereof.

[0121] Radiation therapy includes, but is not limited to, exposure to radiation, e.g., ionizing radiation, UV radiation, as known in the art. Exemplary dosages include, but are not limited to, a dose of ionizing radiation at a range from at least about 2 Gy to not more than about 10 Gy or a dose of ultraviolet radiation at a range from at least about 5 J / m2to not more than about 50 J / m2, usually about 10 J / m2.

[0122] In some embodiments, the methods further comprise sequentially, separately, or simultaneously administering an immunotherapy to the subject. In some embodiments, the immunotherapy regulates immune checkpoints. In further embodiments, the immunotherapy comprises, or consists essentially of, or yet further consists of an immune checkpoint inhibitor, such as a Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) inhibitor, or a Programmed Cell Death 1 (PD-1) inhibitor, or a Programmed Death Ligand 1 (PD-L1) inhibitor. In yet further embodiments, the immune checkpoint inhibitor comprises, or consists essentially of, or yet further consists of an antibody or an equivalent thereof recognizing and binding to an immune checkpoint protein, such as an antibody or an equivalent thereof recognizing and binding to CTLA4 (for example, Yervoy (ipilimumab), CP-675,206 (tremelimumab), AK104 (cadonilimab), or AGEN1884 (zalifrelimab)), or an antibody or an equivalent thereof recognizing and binding to PD-1 (for example, Keytruda (pembrolizumab), Opdivo (nivolumab), Libtayo (cemiplimab), Tyvyt (sintilimab), BGB-A317 (tislelizumab), JS001 (toripalimab), SHR1210 (camrelizumab), GB226 (geptanolimab), JS001 (toripalimab), AB 122 (zimberelimab), AK105 (penpulimab), HLX10 (serplulimab), BCD-100 (prolgolimab), AGEN2034 (balstilimab), MGA012 (retifanlimab), AK104 (cadonilimab), HX008 (pucotenlimab), PF-06801591 (sasanlimab), JNJ-63723283 (cetrelimab), MGD013 (tebotelimab), CT-011 (pidilizumab), or Jemperli (dostarlimab)), or an antibody or an equivalent thereof recognizing and binding to PD-L1 (for example, Tecentriq (atezolizumab), Imfinzi (durvalumab), Bavencio (avelumab), CS1001 (sugemalimab), orKN035 (envafolimab)).-40- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0123] In some embodiments, the methods further comprise sequentially, separately, or simultaneously administering a cytokine to the subject. In some embodiments, the cytokine is administered prior to, during, or subsequent to administration of the one or more MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs disclosed herein. In some embodiments, the cytokine is selected from the group consisting of interferon a, interferon P, interferon y, complement C5a, IL-2, TNFa, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2.

[0124] The methods for treating U2AF1 -mutant cancer may further comprise sequentially, separately, or simultaneously administering to the subject at least one chemotherapeutic agent, optionally selected from the group consisting of nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, gemcitabine, triazenes, folic acid analogs, anthracyclines, taxanes, COX-2 inhibitors, pyrimidine analogs, purine analogs, antibiotics, enzyme inhibitors, epipodophyllotoxins, platinum coordination complexes, vinca alkaloids, substituted ureas, methyl hydrazine derivatives, adrenocortical suppressants, hormone antagonists, endostatin, taxols, camptothecins, SN-38, doxorubicin, doxorubicin analogs, antimetabolites, alkylating agents, antimitotics, anti -angiogenic agents, tyrosine kinase inhibitors, mTOR inhibitors, heat shock protein (HSP90) inhibitors, proteosome inhibitors, HD AC inhibitors, pro-apoptotic agents, methotrexate and CPT-11.Kits of the Present Technology

[0125] The presently disclosed subject matter provides kits for the treatment of U2AF1-mutant cancer. In certain embodiments, the kit comprises (a) any and all embodiments of the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs disclosed herein and (b) a delivery vehicle (e.g., plasmid, lipid nanoparticle (LNP)).-41- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0126] In some embodiments, the kit comprises a sterile container; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments. If desired, the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs of the present technology can be provided together with instructions for administering the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs to a subject having U2AF1 -mutant cancer. The instructions will generally include information about the use of the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs disclosed herein for the treatment of U2AF1 -mutant cancer. In other embodiments, the instructions include at least one of the following: description of the therapeutic agent; dosage schedule and administration for treatment or prevention of cancer or symptoms thereof; precautions; warnings; indications; counter-indications; overdose information; adverse reactions; animal pharmacology; clinical studies; and / or references. The instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.

[0127] The MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs of the present technology may be provided in the form of a prefilled syringe or autoinjection pen containing a sterile, liquid formulation or lyophilized preparation (e.g., Kivitz etal., Clin. Ther. 28:1619-29 (2006)).

[0128] A device capable of delivering the kit components through an administrative route may be included. Examples of such devices include syringes (for parenteral administration) or inhalation devices.

[0129] The kit components may be packaged together or separated into two or more containers. In some embodiments, the containers may be vials that contain sterile, lyophilized formulations of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs that are suitable for reconstitution. A kit may also contain one or more buffers suitable for reconstitution and / or dilution of other reagents. Other containers that may be used include, but are not limited to, a pouch, tray, box, tube, or the like. Kit components may be packaged and maintained sterilely within the containers.-42- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0130] Also provided herein are kits for use in the manufacture of vectors comprising the MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B synthetic intron constructs disclosed herein.EXAMPLES

[0131] The present technology is further illustrated by the following Examples, which should not be construed as limiting in any way.Example 1: Therapeutic Approaches Targeting Spliceosome-mutant MDS

[0132] The frequency and neom orphic nature of RNA splicing factor mutations in combination with the need for new therapies for myeloid malignancies has made spliceosome genetic alterations exciting candidates for therapeutic targeting. The Examples described herein utilize a “synthetic introns” approach11that takes advantage of mutant SF3B1 -dependent mis-splicing to selectively eliminate malignant cells (FIG. 1). This approach was previously used to drive expression of therapeutic payloads in SF3B 7-mutant cancer cells with high specificity, leaving healthy wild-type cells (WT) unaffected. The synthetic intron approach was recently used to discover that the previously poorly characterized protein GPATCH8 is required for pathologic splicing events and impaired hematopoiesis in 5F3B7-mutant cells12.

[0133] As demonstrated herein, synthetic introns that are uniquely sensitive to mutations in U2AF1 were created. U2AF1 mutations are common in patients with MDS and AML3,4and are associated with adverse risk in AML, MDS13, as well as subjects with clonal hematopoiesis and clonal cytopenias of undetermined significance.14'16Example 2: Synthetic Introns can Mimic U2AF1 Mutation-dependent Mis-splicing

[0134] Endogenous genes that responded strongly and consistently to the most common U2AF1 mutations were identified (those at the S34 residue; FIG. 2A).

[0135] We analyzed RNA-seq data from 263 patients with AML with U2AF1 S34 mutations or without any mutations in RNA splicing factors as well as isogenic human AML K562 cells with or without knockin of U2AF1 S34F or S34Y mutations. This revealed a series of 3’ splice sites which were consistently aberrantly spliced in U2AF S34 mutant AML cells (FIGs. 2B-2C). U2AF1 S34 mutant cells change 3’ splice site usage in a sequence-specific manner based on the identity of the nucleotide immediately upstream of the 3’ AG dinucleotide17. This finding was confirmed in RNA-seq analyses where U2AF1 S34 mutant cells preferred 3’ splice sites bearing a C nucleotide just upstream of the 3’ -43- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526splice site while skipping splice sites marked by a U (FIG. 2D). This change in 3’ splice site usage is exemplified by events in three genes- MTA1, PRUNE1, and TRMT13- where U2AF1 S34F and S34Y mutant AML cells consistently utilized a distal 3’ splice site compared to U2AF1 WT cells (FIGs. 2E, 2G, 21). The entire endogenous intron of each of these three mRNAs and its alternative 3’ splice sites were inserted to interrupt the cDNA sequence encoding the suicide gene HSV-TK. HSV-TK is inert in cells until the prodrug ganciclovir is provided, which leads to cytotoxic metabolite production. Expression of the MTA1 -HSV-TK construct in U2AF1S34F / Y mutant cells yielded a full-length HSV-TK mRNA and protein. In contrast, U2AF1 WT cells expressed an incompletely spliced, nonfunctional mRNA and, as such, only U2AF1 mutant cells were killed with ganciclovir treatment while U2AF1 WT cells were unaffected.

[0136] Following the above observations, the intron and its alternative 3’ splice sites in MTA1 were inserted to interrupt the cDNA sequence encoding the suicide gene HSV-TK (FIG. 2K) HSV-TK is an enzyme which is normally inert in cells but in the presence of the FDA-approved anti-viral medication ganciclovir, HSV-TK phosphorylates ganciclovir allowing the drug to block DNA synthesis. Using these constructs, it was hypothesized that U2AF1 mutant cells would excise the entire intron and yield an uninterrupted HSV-TK cDNA and protein, thereby allowing U2AF1 mutant cells to be killed upon exposure to ganciclovir. In contrast, U2AF1 WT cells would utilize the intron proximal 3’ splice site (marked by “TAG”) and give rise to an incompletely spliced and non-functional mRNA that would not produce HSV-TK protein (FIG. 2K). This hypothesis was confirmed upon RT-PCR for spliced HSV-TK in AML cells with or without knockin of the U2AF1S34Y / WTmutation bearing these constructs (FIG. 2M). Furthermore, when we exposed these same cells to ganciclovir, only the U2AF1 mutant cells were killed while U2AF1 WT cells were unaffected by ganciclovir treatment (FIG. 2N).

[0137] In the above constructs, the entire 268 base pair endogenous intron of MTA1 as well as the region between the competing 3’ splice sites (consisting of an additional 47 nucleotides) were inserted into HSV-TK (FIG. 2K).

[0138] In prior studies creating SF3B1 mutant synthetic introns, endogenous introns were shortened to create sequences <250 nucleotides in length11. This shortening of introns was done to (1) facilitate efficiency of in vivo delivery (as shorter sequences are more efficiently delivered and expressed in cells) and (2) enable massively parallel screening of-44- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526synthetic intron variant libraries (where high-throughput synthesis of the library is limited to cDNA sequences <250 nucleotides). 315 nucleotide MTA1 endogenous natural introns were shortened by ligating the minimal sequences at the 5’ end (30 nucleotides) and 3’ end (148 nucleotides) of the endogenous intron to form a new synthetic version of the endogenous intron (FIG. 20).Example 3: SpliceAI Deep Learning Enables Synthetic Intron Optimization

[0139] When the shortened synthetic version of MTA1 intron within HSV-TK was expressed, there was preferential killing of U2AF1S34F / WTand U2AF1S34Y / WTcells but U2AF1WTcells were killed at higher dose of ganciclovir indicating some loss of differential splicing activity occurred with shortening the intron (Fig. 2P). The mutant selectivity of the synthetic introns for U2AF1 mutant cells was improved. Previous studies utilized massively parallel functional genomic screens with libraries of thousands of variant introns to improve the mutant selectivity of synthetic introns in an unbiased manner12. At the same time, the recent development of the deep learning method SpliceAI to predict splicing site usage and the impact of mutations on splicing18enabled high-throughput in silico mutagenesis to modify the synthetic introns for U2AF1 to promote differential splicing activity of the MTA1 synthetic intron.

[0140] To enable massively parallel screening, optimize mutant selectivity, and allow for in vivo delivery, we next reduced the size of the natural 315 base pairs MTA1 intron form a new 208 base pairs synthetic intron. FIG. 4A: Workflow of MTA1 synthetic intron improvement. The splice site strength of each of the two competing 3’ splice sites in the HSV-TK cDNA disclosed herein interrupted by the MTA synthetic intron was computed. The analysis revealed that the intron-proximal 3’ splice site (which would be ideally utilized only in U2AF1 WT cells) had a strength of 0.2528, while the distal 3’ splice site (which would be ideally used only in U2AF1 mutant cells) had a strength of 0.7549 (FIG. 3A).624 mutations were evaluated in silico throughout the intron to identify potential mutations which would strengthen the intron-proximal 3’ splice site in U2AF1 WT cells while simultaneously reducing usage of the distal 3’ splice site (FIG. 3B).

[0141] We performed a massively parallel functional screen with 12,000 variant introns. Overall, we identified intron variants that strengthen the intron-proximal 3’ splice site by base pairing with U2snRNA in WT cells while strengthen the distal 3’ splice site by stabilizing U2AF2 recognition in S34F mutant cells.-45- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526

[0142] 6 of these mutations within the synthetic MTA1 intron were then created and one single nucleotide variant within the MTA1 synthetic intron that created optimal differential splicing activity between U2AF1 WT and mutant cells was identified. The single nucleotide variant within the MTA1 synthetic intron resulted in ganciclovir-mediated killing in U2AF1 mutant cells while completely sparing U2AF1 WT cells (FIGs. 3C-3E).Moreover, when isogenic AML WT cells or U2AF1 mutant cells bearing the MTA1 synthetic intron construct were introduced into NSG mice, ganciclovir treatment of mice promoted survival of U2AF1 mutant cells by a median of 20 days relative to the untreated group (p=0.0015; ganciclovir did not alter survival of mice engrafted with U2AF1 WT cells), indicating efficacy of this approach (FIGs. 3F-3G). FIGs. 4B-4H demonstrate that the synthetic introns of the present technology show exclusive killing in U2AF1 mutant cancer cells both in vitro and in vivo.Example 4: In vivo Synthetic Intron Delivery for Treating U2AFl-mutant Hematopoietic Malignancies

[0143] A preclinical in vivo study (FIG. 3F) demonstrates that the MTA1 synthetic intron selectively targeted U2AF1 mutant cells in NSG mice engrafted with U2AF1 isogenic leukemic cells.

[0144] We next evaluated lipid nanoparticles (LNPs) for in vivo delivery of the lead U2AF1 mutant-selective synthetic introns. While LNPs are a clinically advanced RNA delivery vehicle, they yield minimal import of RNA cargo into cell nucleus (the site of RNA splicing). We therefore tested delivery of plasmid DNA in LNP formulations. This approach enabled nearly 80% nuclear expression in myeloid leukemia cells and 7% nuclear expression in AML cells engrafted NSG mice. FIGs. 5A-5H depict nano-plasmid mediated delivery of synthetic introns.

[0145] Now, the synthetic introns derived therapeutic payload in plasmid DNA that are encapsulated in LNPs are being tested in vivo. We aim to use ionizable LNPs for mRNA delivery to leukemic cells in vivo. LNPs have shown remarkable promise for nucleic acid delivery in vivo and are currently the most clinically advanced delivery vehicle for RNA delivery as demonstrated by their use in COVID-19 mRNA vaccines.24LNPs possess key advantages over viral and other non-viral RNA delivery vehicles, including: (i) preventing degradation of nucleic acid cargo by serum endonucleases in blood, (ii) avoiding renal clearance from the bloodstream, (iii) delivering RNA cargo to specific cells and-46- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526tissues via functionalization with targeting ligands and / or tailoring LNP surface chemistry, and (iv) mediating target cell entry and endosomal escape.25,26Thus, we propose to exploit LNP features to develop a targeted delivery system for the in vivo delivery of MTA1 synthetic intron mRNA to leukemic cells.

[0146] We will investigate both non-targeted and targeted delivery of mRNA LNPs to mutant cells in vivo. We will formulate LNPs encapsulating MTA 1 synthetic intron mRNA using FDA-approved and gold standard ionizable lipids (such as SM-102 or ALC-0315, and Dlin-MC3-DMA or C12-200, respectively), helper lipids, lipid-PEG and cholesterol (FIG. 7A). This composition can enhance endosomal escape and potent intracellular delivery; stabilize the particles, promote membrane fusion and prevent aggregation. Initially, we will administer the synthetic intron mRNA LNPs intravenously into xenograft mouse model to evaluate their efficacy. In these experiments GFP is also constitutively encoded by the LNP allowing us to evaluate efficiency of general cellular uptake. Given that many LNPs often accumulate in the liver24, we will assess the maximal on-target effects in myeloid cells, especially within nuclei where RNA splicing occurs. For targeted delivery, we are conjugating the fragment antigen-binding region of specific antibodies which are present on myeloid malignant cells (including CD33, CD90, and E-selectin) to LNPs. Our preliminary data delivering CD38-conjugated LNPs encapsulating mRNA encoding GFP in vivo already demonstrate proof of concept of this approach to other hematologic malignancy types (FIGs. 7B-7C). It is anticipated that the targeted approach may enhance specific cellular uptake and endosomal escape of lipid nanoparticle.Example 6: Identifying Cis-acting Features that Underlie the Splicing Effects of U2AF1 S34 Mutations

[0147] Rationale: It is hypothesized that the functional screens described herein will reveal novel mechanistic insight into the pre-mRNA sequences that govern mutant U2AF1 function that can be exploited for therapeutic intent.

[0148] Methods: Here we will build on our preliminary data by subjecting our shortened endogenous A 74 / -derived synthetic introns, to our workflow for synthetic intron optimization (as in FIG. 6)19. We have computationally designed a large (-11,816 synthetic intron variants) library for the parent synthetic intron and will mutagenize the nucleotides between the competing 3’ splice sites (e.g., mutagenesis of every two nucleotides) as well as creating many versions of the polypyrimidine tract given present-47- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526understanding of how mutant U2AF1 alters splicing (FIG.6). We will also incorporate saturation mutagenesis and sliding deletion scanning as additional strategies to comprehensively investigate all residues within the intron (FIG.8). The library will be synthesized via oligonucleotide array and introduced into HSV-TK cDNA. We will perform a negative selection screen as in our previously published papers19,20with K562 cells with or without knockin of the U2AF1^^ and U2AF1^ mutation to identify synthetic introns which drive efficient cell killing in A2d / ’7-mutant cells but not WT cells. We will then validate optimized synthetic intron splicing and protein production by introducing the synthetic intron constructs into primary human healthy control cells (n=5) and cells from patients with U2AF1 -mutant myeloid leukemias (n=5). Genotype-dependent alternative splicing in primary cells will be assessed by RT-PCR, fluorescent reporters, and HSV-TK killing assay. Additionally, we will transduce primary U2AF1 mutant leukemia cell samples (n=5 different patient samples) with optimized U2AF1 synthetic introns and generate patient derived xenograft models in NSG-S mice (NOD / SCID IL2Rg-null mice with transgenic expression of human GM-CSF, IL-3 and SCF)21(n=10 mice / patient sample). Engraftment will be checked with human CD45+CD33+antibodies and mice will be treated with ganciclovir as previously described19.Example 7: Identifying Trans-acting Splicing Factors Required for Mutant U2AF1 Mis-splicing Activity

[0149] Rationale: Here we will utilize U2AF1 mutant responsive synthetic introns to systematically screen for trans factors required for mutant U2AF1 aberrant splicing activity.

[0150] Methods: In addition to the constructs shown in FIG.3 whereby expression of mutant U2AF1 drives expression of a protein of interest, we have also created versions where expression of mutant U2AF1 interrupts expression of a protein. Specifically, we have created fluorescent reporters where GFP is expressed in U2AF1 WT cells but mis-splicing in U2AF1 S34 mutant cells interrupts GFP expression. Using this approach, we will perform whole genome CRISPR screens to identify genes whose knockout (KO) promotes GFP expression (thereby indicating correction of mutant U2AF1 mis-splicing activity). These screens will be performed in human leukemia (K562) cell lines with or without knockin of U2AF1 S34F and S34Y mutations. Following transduction and stable selection of the Brunello whole-genome CRISPR sgRNA library in these cells, the top and bottom 10% of GFP expressing cells will be sorted and sequenced to compare sgRNAs-48- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526enriched in these populations. A very similar approach was used in a recent publication from our group to identify proteins required for cells with cancer-associated mutations in the core RNA splicing factor SF3B123. The experiment will be conducted in biological triplicate in each cell line bearing each reporter, and we will search for genes where >3 sgRNAs were statistically enriched (defined as / ?-value<0.001).

[0151] Lead candidate hits will be independently validated by assessing GFP florescent expression and RT-PCR synthetic intron splicing patterns following KO of each candidate with 3 independent sgRNAs. Additionally, we will measure mis-splicing of endogenous transcripts of well-characterized U2AF1 mis-splicing events (e.g., splicing events in MTA1 (e.g., UniProt ID: Q13330), PRUNE1 (e.g., UniProt ID: Q86TP1), and TRMT13 (e.g., UniProt IDs: Q5VVL2, Q5VVK9, and Q9NUP7). Finally, we will assess the impact of KO of the strongest lead candidate on the full constellation of U2AF1 mis-spliced transcripts through RNA-sequencing of cells with or without lead candidate KO. Later downstream studies of previously poorly characterized proteins will include experiments to determine their cellular localization (cytoplasmic, nuclear, soluble nuclear, in nuclear speckles, etc.) using immunofluorescence and immunoprecipitation / mass spectrometry to understand protein interactions with WT and mutant U2AF1.EQUIVALENTS

[0152] The present technology is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the present technology. Many modifications and variations of this present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the present technology, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the present technology. It is to be understood that this present technology is not limited to particular methods, reagents, compounds compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0153] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby -49- 4904-0631-6176.1Atty. Dkt. No.: 115872-3526described in terms of any individual member or subgroup of members of the Markush group.

[0154] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a nonlimiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.

[0155] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.REFERENCES1. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 ;365(15): 1384- 1395.2. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-2506.3. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.4. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012;44(l):53-57.5. Quesada V, Ramsay AJ, Lopez-Otin C. Chronic lymphocytic leukemia with SF3B1 mutation. N Engl J Med. 2012;366(26):2530.-50- 4904-0631-6176.1Atty. Dkt. No.: 115872-35266. Kim E, Hagan JO, Liang Y, et al. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell. 2015;27(5):617-630.7. Yoshimi A, Lin KT, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574(7777):273-277.8. Liu ZQ, Yoshimi A, Wang JG, et al. Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. Cancer Discovery . 2020;10(6):806-821.9. Hagan JO, Ramakrishnan A, Hayes B, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25(1): 14-26.10. Shirai CL, Ley JN, White BS, et al. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell. 2015;27(5):631-643.11. North K, Benbarche S, Liu B, et al. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nat Biotechnol . 2022;40(7): 1103-1113. 12. Benbarche S, Pineda JMB, Galvis LB, et al. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies. Mol Cell. 2024.13. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;l(7):EVIDoa2200008.14. Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24(7): 1015-1023.15. Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400-404.16. Weeks LD, Niroula A, Neuberg D, et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2023 ;2(5).17. Hagan JO, Ramakrishnan A, Hayes B, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome research. 2015;25(1): 14-26.18. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019;176(3):535-548 e524. 19. North K, Benbarche S, Liu B, et al. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nat Biotechnol . 2022.20. Lee SC, North K, Kim E, et al. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell. 2018;34(2):225-241 e228.-51- 4904-0631-6176.1Atty. Dkt. No.: 115872-352621. Yoshimi A, Balasis ME, Vedder A, et al. Robust patient-derived xenografts of MDS / MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017;130(4):397-407.22. Benbarche SP, J.M.B.; Galvis, L.B.; Liu, B.; Biswas, J.; Wang, E.; Lyttle, K.A.; Lewis, A.M.; Sarchi, M.; Mehta, S.; Garippa, R.; Ortiz-Pacheco, J.; Li, Z.; Monetti, M.; Stanley, R.; Doulatov, S.; Bradley, R.K; Abdel -Wahab, O. Synthetic Introns Identify the Novel RNA Splicing Factor GPATCH8 As Required for Mis-Splicing Induced By SF3B1 Mutations. Blood. 2023; 142:3.23. Benbarche S, Pineda JMB, Galvis LB, et al. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies. Mol Cell. 2024;84(10):1886- 1903 el810.24. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094.25. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2): 129-138.26. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8): 541 -555.27. Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood.2017;130(15):1699-1705.28. Stiff A, Fornerod M, Kain BN, et al. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024.29. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627; quiz 3699.-52- 4904-0631-6176.1

Claims

1. Atty. Dkt. No.: 115872-3526WHAT IS CLAIMED IS1. A synthetic intron construct comprising (a) a heterologous promoter and (b) an intron domain derived from a naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B, wherein the heterologous promoter is located upstream of the intron domain.

2. The synthetic intron construct of claim 1, wherein the length of the intron domain is about 200-600 base pairs (bps).

3. The synthetic intron construct of claim 1 or 2, wherein the intron domain comprises (i) a 5' splice site, (ii) a canonical 3' splice site, and (iii) at least one cryptic 3' splice site.

4. The synthetic intron construct of any one of claims 1-3, wherein the intron domain comprises a sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to a sequence derived from the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B.

5. The synthetic intron construct of any one of claims 1-4, wherein the naturally occurring intron sequence of MTA1, PRUNE1, TRMT13, POLB, RNF216, or DNMT3B comprises intron 13 of MTA1, intron 6 of TRMT13, intron 2 of PRUNE1, intron 6 of POLB, intron 4 of RNF216, or intron 4 of DNMT3B.

6. The synthetic intron construct of any one of claims 1-5, wherein the intron domain derived from the naturally occurring intron sequence of MT Al, PRUNE 1, TRMT13, POLB, RNF216, or DNMT3B is flanked by an upstream first exon domain and a downstream second exon domain.

7. The synthetic intron construct of claim 6, wherein the synthetic intron construct comprises intron 13 of MTA1 flanked by exon 13 and exon 14, intron 6 of TRMT13 flanked by exon 6 and exon 7, intron 2 of PRUNE1 flanked by exon 2 and exon 3, intron 6 of POLB flanked by exon 6 and exon 7, intron 4 of RNF216 flanked by exon 4 and exon 5, or intron 4 of DNMT3B flanked by exon 4 and exon 5.

8. The synthetic intron construct of any one of claims 1-7, wherein the synthetic intron construct comprises the sequence of any one of SEQ ID NOs: 1-90.

9. The synthetic intron construct of any one of claims 1-8, wherein the synthetic intron construct is differentially spliced in a cell comprising a mutation in U2AF1,-53--0631-6176.1Atty. Dkt. No.: 115872-3526optionally wherein the intron domain is (i) entirely spliced out in the cell comprising the mutation in U2AF1, and is (ii) partially spliced out in a cell without the mutation inU2AFL10. The synthetic intron construct of claim 9, wherein the mutation in U2AF1 is S34F or S34Y.

11. The synthetic intron construct of any one of claims 1-10, further comprising a fluorescent protein.

12. The synthetic intron construct of claim 11, wherein the fluorescent protein is TagBFP, Azurite, EBFP2, mKalamal, Sirius, Sapphire, T-Sapphire, ECFP, Cerulean, SCFP3A, mTurquoise, monomeric Midoriishi-Cyan, TagCFP, mTFPl, EGFP, Emerald, Superfolder GFP, Monomeric Azami Green, TagGFP2, mUKG, mWasabi, EYFP, Citrine, Venus, SYFP2, TagYFP, Monomeric Kusabira-Orange, mKOK, mK02, mOrange, mOrange2, mRaspberry, mCherry, dsRed, mStrawberry, mTangerine, tdTomato, TagRFP, TagRFP-T, mApple, mRuby, mPlum, HcRed- Tandem, mKate2, mNeptune, NirFP, TagRFP657, IFP1.4, iRFP, mKeima Red, LSS- mKatel, LSS-mKate2, PA-GFP, PAmCherryl, PATagRFP, Kaede (green), Kaede (red), KikGRl (green), KikGRl (red), PS-CFP2, PS-CFP2, mEos2 (green), mEos2 (red), PSmOrange, or Dronpa.

13. The synthetic intron construct of any one of claims 1-12, further comprising a suicide gene, optionally wherein the intron domain is inserted between a first exon domain of the suicide gene and a second exon domain of the suicide gene, or wherein the suicide gene is herpes simplex virus thymidine kinase (HSV-TK) or inducible caspase 9 (iCasp9).

14. The synthetic intron construct of any one of claims 1-13, further comprising a cytokine selected from among interferon a, interferon P, interferon y, complement C5a, IL-2, TNFalpha, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4,-54--0631-6176.1Atty. Dkt. No.: 115872-3526CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2.

15. The synthetic intron construct of claim 14, wherein the cytokine and the intron domain are separated by a cleavable linker.

16. The synthetic intron construct of claim 15, wherein the cleavable linker is a 2A selfcleaving peptide linker selected from the group consisting of P2A, T2A, E2A, F2A and BmCPV2A.

17. The synthetic intron construct of any one of claims 1-16, wherein the heterologous promoter is an inducible promoter, or a constitutive promoter.

18. A method for treating a U2AF1 mutant cancer in a subject in need thereof comprising administering to the subject an effective amount of the synthetic intron construct of any one of claims 13-17.

19. The method of claim 18, wherein the U2AF1 mutant cancer is selected from among myelodysplastic syndromes (MDS), myeloid cancer (e.g., AML), lung cancer, and pancreatic cancer.

20. A method for identifying a drug candidate that inhibits mis-splicing in a U2AF1 mutant cancer cell comprising contacting the U2AF1 mutant cancer cell with an effective amount of the synthetic intron construct of any one of claims 13-17, contacting the U2AF1 mutant cancer cell with a drug candidate, and measuring proliferation of the U2AF1 mutant cancer cell.

21. The method of claim 20, wherein the drug candidate is a small molecule or an inhibitory RNA (e.g., siRNA, shRNA, sgRNA or antisense).

22. The method of claim 20 or 21, wherein the synthetic intron construct is administered orally, intranasally, parenterally, intravenously, intramuscularly, intraperitoneally, or subcutaneously, rectally, intrathecally, intratumorally or topically.

23. The method of any one of claims 18-22, wherein the synthetic intron construct is formulated with a lipid nanoparticle (LNP).

24. The method of claim 23, wherein the LNP comprises a receptor that targets the U2AF1 mutant cancer cell.

25. The method of claim 24, wherein the receptor is a Fab, a Fab’, a scFv, or a (Fab)2.

26. The method of claim 24 or 25, wherein the receptor targets a ligand expressed on the cell surface of the U2AF1 mutant cancer cell.-55--0631-6176.1